Drug, bio-affecting and body treating compositions inventions 04/07

20070093410 - Selective inhibition of proteasomes of tuberculosis and other bacteria: Compositions and methods for inhibiting bacterial proteasomes are provided. Methods of screening antibacterial compounds, methods of treating bacterial infections and disorders associated with bacterial infections, and methods of treating polyglutamine disorders are also provided.... Agent: Banner & Witcoff, Ltd.

20070093411 - Zinc-free and low-zinc insulin preparations having improved stability: The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin analog, and an insulin derivative; at least one surfactant; optionally at least one preservative; and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is... Agent: Novo Nordisk, Inc. Patent Department

20070093414 - Hepatitis c virus inhibitors: e

20070093413 - Histone deacetylases, and uses related thereto: The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070093412 - Pharmaceutical composition comprising cyclic somatostatin analogues: The present invention describes parenteral pharmaceutical compositions comprising a somatostatin analogue and novel somatostatin analogues.... Agent: Novartis Corporate Intellectual Property

20070093415 - Amyloid specific peptides and uses thereof: Phage peptide display technology was used to identify peptides that bind specifically to the amyloid form of the Aβ1-40 peptide. Peptides with similar structural features and bind to the amyloid form of Aβ1-40 but not to monomeric Aβ1-40, are provided. Such peptides are useful as carrier molecules to deliver therapeutic... Agent: Buchanan, Ingersoll & Rooney LLP

20070093421 - Bio-security system: A method for preventing contamination of a teat during administration of a sealant comprises the steps of introducing/delivering a sterilising agent into the teat and subsequently delivering the sealant into the teat. A sealant injector 1, has a nozzle 3, with a removable protective cap 2. A sterilising agent 4... Agent: Jacobson Holman PLLC

20070093422 - Drug comprising synthetic peptide analogs for the treatment of cancer: The present invention relates to a combination of peptides that may be used for treatment of cancer. The peptide combination competes for the binding of specific neuropeptides at the plasma membrane and thereby alters the levels of key intracellular molecules implicated in cell proliferation, resulting in a broad spectrum of... Agent: Ladas & Parry

20070093416 - Human beta-defensin secretion promoter: The present invention provides a human β-defensin secretion promoter that can be used in various forms, such as external preparation, internal preparation, food, etc., and promotes human β-defensin secretion. An organic acid has an effect of promoting the secretion of human β-defensin, particularly human β-defensin-2, and therefore the organic acid... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070093418 - Methods of treatment using specific binding agents of human angiopoietin-2: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.... Agent: Marshall, Gerstein & Borun LLP

20070093419 - Methods of treatment using specific binding agents of human angiopoietin-2: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.... Agent: Marshall, Gerstein & Borun LLP

20070093417 - Novel glp-1 analogues linked to albumin-like agents: Novel GLP-1 agonists which are protracted by coupling to a protraction protein.... Agent: Novo Nordisk, Inc. Patent Department

20070093420 - Therapy procedure for drug delivery for trigeminal pain: The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region.... Agent: Morrison & Foerster LLP

20070093423 - Process for production of bivalirudin: The invention relates to methods for the preparation of high purity Bivalirudin. The polypeptide is prepared in a high purity of at least 98.5% (by HPLC), wherein the total impurities amount to less than 1.5%, comprising not more than 0.5% [Asp9-Bivalirudin] and each is impurity less than 1.0%, and preferably... Agent: Kenyon & Kenyon LLP

20070093424 - Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases: Small molecule polycationic agents are used to modulate or interrupt biological processes by binding to oligosaccharide-based biomolecules. Compounds that inhibit nitric oxide, TNFα or other immunomodulators are provided and are useful for treating immunological disease and disease of an infectious disorder.... Agent: Connolly Bove Lodge & Hutz LLP

20070093426 - Histone h2a peptide derivatives and analogs and methods of use thereof: Peptides derived from a segment of human histone H2A, the segment corresponding to amino acid residues 36-44 of human histone H2A, are capable of reducing or ameliorating the extent of injury induced by noxious stimuli when administered to animals. Pharmaceutical compositions and methods of using these peptides are also disclosed.... Agent: Winston & Strawn LLP Patent Department

20070093427 - Membrane-permeable nfat inhibitory peptide: The present invention aims to solve the conventional problems by providing a peptide compound, in which when administered to a patient of immunologic disease, cardiac hypertrophy or a disease caused by NFAT activation, the period from administration to actual exhibition of effectiveness is short and there are no side effects... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070093425 - Vitamin c derivatives with peptide, preparation method thereof and composition comprising the same: Disclosed are vitamin C derivatives linked with a peptide or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a composition comprising the same.... Agent: Medlen & Carroll, LLP

20070093428 - Iap bir domain binding compounds: s

20070093429 - Iap bir domain binding compounds:

20070093431 - Combination of organic compounds: The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof and at least one antidiabetic agent.... Agent: Novartis Corporate Intellectual Property

20070093430 - Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070093432 - Camptothecin derivatives as chemoradiosensitizing agents: Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group... Agent: Foley & Lardner LLP

20070093433 - Aminoglycoside antibiotics for use as vap-1/ssao inhibitors: The present invention concerns the use of a compound comprising one or more sugar moieties, which optionally are aminosubstitutes, and possibly other moieties, wherein said compound is a molecule comprising at least two aminosubstituents, said aminosubstituents being primary, secondary or tertiary amino groups, wherein said aminosubstituents are either attached to... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070093441 - Antigen arrays for treatment of allergic eosinophilic diseases: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an array comprising a protein or peptide of IL-5, IL-13 or eotaxin. More specifically, the invention provides... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070093444 - Chromatin peptides blocking human hif-1alpha gene and modulating the downstream related genes: Chromatin peptide drug molecules, which can block human cell hypoxia responsive pathway, are DNA affinity structural domain of related transcription genes or their imitating molecules or derivatives, containing 5-100 amino acid residues which can specifically bind firmly to HIF-1α gene self promoter or its downstream regulated more than 40 gene... Agent: Frank S. Digiglio Scully, Scott, Murphy & Presser, P.C.

20070093436 - Drop1, a novel marker for carcinogenesis: Described is a novel marker protein associated with epithelial tumors, e.g., ovarian, mammary, stomach, kidney, thyroid and lung carcinomas, Dropl, a dystrophin-related protein as well as a nucleic acid molecule encoding Dropl. Furthermore, various diagnostic and therapeutic uses based on the finding that the expression of Dropl is downregulated in... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070093440 - Medical treatment: An RNAi agent targets a component of a human Notch signalling pathway other than presenilin1 or presenilin2 by RNA interference to reduce expression of said component.... Agent: Frommer Lawrence & Haug

20070093443 - Modified proteases that inhibit complement activation: Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be... Agent: Stephanie Seidman Fish & Richardson P.C.

20070093435 - Modulation of cell phenotype by inhibitory rna: We describe a method to inhibit cell division of hyperproliferative cells, typically cancer cells, by introducing inhibitory RNA (RNAi) into said cells to ablate mRNAs that encode polypeptides involved in cellular processes and including RNAi molecules and vectors including transcription cassettes encoding said RNAi molecules. By application of said RNAi... Agent: Klarquist Sparkman, LLP

20070093442 - Modulation of mesenchymal and metastatic cell growth: The present invention relates to compositions and methods for the modulation of metastatic and mesenchymal cell growth and mobility via the regulation of the formation of Twist/Twist homodimers and Twist/E heterodimers. The present invention also relates to methods for screening agents and compound libraries for molecules that function to modulate... Agent: Kevin Farrell Pierce Atwood

20070093434 - Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus: Methods of reducing food intake and glucose production in a mammal, or restoring hepatic autoregulation are provided. The methods involve increasing long-chain fatty acyl-Co-A (LC-CoA) levels in the hypothalamus, or stimulating efferent fibers in the hepatic branch of the vagus nerve. Also provided are methods of increasing food intake and... Agent: Myers Bigel Sibley & Sajovec

20070093437 - Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating XIAP gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of XIAP gene expression and/or activity by... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070093445 - Rna interference mediating small rna molecules: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070093439 - Short immunomodulatory oligonucleotides: The invention relates to modulation of the immune system. More particularly, the invention relates to modulating the immune system through the use of oligonucleotide-derived compounds. The invention provides immunostimulatory agents that are less expensive to make than existing immunostimulatory oligonucleotides. The immunostimulatory agents according to the invention can, in preferred... Agent: Joseph C. Zucchero Keown & Associates

20070093438 - Use of eukaryotic genes affecting spindle formation or microtubule function during cell division for diagnosis and treatment of proliferative diseases: The present invention relates to the significant functional role of several C. elegans genes and of their corresponding gene products in spindle formation or microtubule function during cell division that could be identified by means of RNA-mediated interference (RNAi) and to the identification and isolation of functional orthologs of said... Agent: Connolly Bove Lodge & Hutz, LLP

20070093446 - Orally bioavailable compounds and methods for inhibiting platelet aggregation: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound,... Agent: Howery LLP

20070093448 - Complexes that consist of vitamin d compounds or analogs thereof with a 5z,7e,10(19)-triene system and methylated derivatives of beta-cyclodextrin: The invention relates to complexes that consist of vitamin D compounds or analogs thereof with a 5Z,7E,10(19)-triene system and methylated derivatives of β-cyclodextrin, in particular a complex that consists of (thiazol-2-yl)-26,27-dinor-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol and heptakis-(2,6-di-O-methyl)-β-cyclodextrin (DIMEB).... Agent: Millen, White, Zelano & Branigan, P.C.

20070093451 - Compositions of estrogen-cyclodextrin complexes: Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since... Agent: Millen, White, Zelano & Branigan, P.C.

20070093447 - Method for crosslinking beta-cyclodextrin for cholesterol trapping and regeneration thereof: Disclosed herein is the use of crosslinked beta-cyclodextrin as a trap for removing cholesterol. The crosslinked beta-cyclodextrin is prepared by crosslinking beta-cyclodextrin in the presence of a crosslinking agent. Treatment with the crosslinked beta-cyclodextrin results in cholesterol-depleted foods. After application to foods, the crosslinked beta-cyclodextrin which traps cholesterol therein can... Agent: Needle & Rosenberg, P.C.

20070093449 - Novel iv formulation of tipifarnib: This invention concerns novel formulations of tipifarnib, which is suitable for intravenous (IV) administration. The invention further concerns the use of such formulation and processes for preparing such formulations and methods of treating by administering said formulations.... Agent: Philip S. Johnson Johnson & Johnson

20070093450 - Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction: The present invention relates to the use of a combination of a PDE5-inhibitor and testosterone for the preparation of a medicament for the treatment of Female Sexual Dysfunction.... Agent: Trask Britt

20070093452 - Use of bivalent or polyvalent trisaccharides as fusion-inhibitors in all hiv types, subtypes, groups, strains, and circulating recombinant forms: This invention relates to compositions containing bivalent or polyvalent trisaccharides, specifically but not exclusively, melezitose and raffinose, and to their use in the treatment/prevention/cure of HIV and AIDS. In particular, such compositions can be used to competitively inhibit formation of the viral fusion complex. This invention also relates to compositions... Agent: Mercedes T. Farquharson

20070093453 - Sulfonamide-substituted chalcone derivatives and their use to treat diseases: i

20070093454 - Pyrimidines and pyrazines useful as modulators of ion channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20070093455 - 10-substituted tetracyclines and methods of use thereof: 10-Substituted tetracycline compounds are described.... Agent: Lahive & Cockfield, LLP

20070093456 - Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis: The present invention is directed to novel derivatives of gambogic acid and analogs thereof. The present invention also relates to the discovery that novel derivatives of gambogic acid are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070093457 - Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid: A composition is provided which comprises an effective amount of curcumin and an effective amount of at least one NSAID for the treatment of cancer and inflammatory diseases and disorders. Also provided are methods of treatment of such diseases and disorders.... Agent: Nath & Associates

20070093458 - Preparation of paricalcitol and crystalline forms thereof: The present invention is directed to a novel process for preparing Paricalcitol wherein Paricalcitol, dissolved in a solvent, is precipitated from a concentrated or seeded solution. The present invention also provides crystalline forms of paricalcitol and processes for their preparations.... Agent: Kenyon & Kenyon LLP

20070093459 - Use of vitamin ds or vitamin d analogs to treat cardiovascular disease: Disclosed are pharmaceutical compositions containing Vitamin D receptor activators or Vitamin D analogs to treat, prevent or inhibit vascular disease. The pharmaceutical compositions may also include ACE inhibitors or other agents. Also disclosed are methods of reducing PAI-1 expression by administering effective amounts of Vitamin D receptor activators or Vitamin... Agent: Robert Deberardine Abbott Laboratories

20070093460 - Methods of using selective 11beta-hsd inhibitors to treat gluocorticoid associated states: Methods for treating glucocorticoid associated states using selective 11β-HSD1-dehydrogenase, 11β-HSD1-reductase and 11β-HSD2 dehydrogenase modulating compounds are described.... Agent: Lahive & Cockfield, LLP

20070093461 - Effect of loteprednol etabonate on vascular dysfunction: This invention relates to the effect of Loteprednol etabonate on vascular dysfunction in the back of the eye. More specifically, this invention relates to methods of modifying a pathogenic angiogenesis in the back of an eye of a patient, the method comprising administering to a patient in need thereof a... Agent: Bausch & Lomb Incorporated

20070093462 - Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients: Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of... Agent: Needle & Rosenberg, P.C.

20070093463 - Radiation enhancement agent for x-ray radiation therapy and boron neutron-capture therapy: Low toxicity halogenated carborane-containing tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy (BNCT), X-ray radiation therapy (XRT) and photodynamic therapy (PDT) for the treatment of tumors of the brain, head and neck, and surrounding tissue. The invention also includes methods of tumor imaging and/or diagnosis... Agent: Brookhaven Science Associates/ Brookhaven National Laboratory

20070093464 - Beta-lactamase resistant cephalosporin ester compounds and salts of thereof: w

20070093465 - Cephem compound: The present invention is concerned with a novel cephem compound, with a process for the production of this compound, which process may contain or consist of fermentative steps, chemical steps, and/or biotransformation steps. A cephem compound according to the present invention characterised by formula (I) or a salt or ester... Agent: Nixon & Vanderhye, PC

20070093466 - Neurotherapeutic treatment for sexual dysfunction: A method for improving sexual function is described. A mammal suffering from sexual dysfunction or otherwise in need of enhanced sexual function is administered a compound selected from those that are capable of inhibiting the activity of β-lactams, penicillin-binding protein, carboxypeptidase,. Such compounds, including particularly β-lactam ring-containing compounds, can be... Agent: Barnes & Thornburg LLP

20070093468 - Methods for treating disorders associated with hyperlipidemia in a mammal: The invention is directed to methods for treating hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitade) and a cholesterol absorption inhibitor (CAI) (for example, ezetimibe). Co-administration of the MTP inhibitor with the CAI produces a therapeutic... Agent: Goodwin Procter LLP Patent Administrator

20070093469 - Substituted azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments: The present invention relates to substituted Azetidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070093467 - Piperidine derivatives and methods of use: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1... Agent: Townsend And Townsend And Crew, LLP

20070093470 - Lxr modulators: m

20070093471 - Compositions and methods for the administration clozapine formulations which modulate body weight: Embodiments of the invention describe compositions and methods for the administration of fast disintegrating atypical antipsychotics which reduce weight in patients previously taking conventional formulation of atypical antipsychotics. In a preferred embodiment said fast dissolving atypical antipsychotic is FAZACLO.... Agent: Knobbe Martens Olson & Bear LLP

20070093472 - 1-[(4-ethynylphenyl)]-2-[(phenyl)]-pyrrolidine-1,2-dicarboxamide derivatives as inhibitors of coagulation factors xa and viia for the treatment of thromboses: Novel compounds of the formula (I), in which R, R1, R2 and R3 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20070093473 - 7-heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents: with the proviso that when Ar1 is a pyridyl group, and Z is —CH2X— where X is attached to the Ar1 group, X is selected from —CH(OR5)—, —NR5— and —CH2— wherein the —CH2— group may be optionally substituted by one or more C1-6alkyl groups. The compounds of formula (I) are... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070093474 - Methods of modulating neurotrophin-mediated activity: Disclosed are compositions which modulate the interaction with nerve growth factor and precursors thereof with neurotrophic receptors. Also disclosed are methods of using the compositions of the invention, including methods of administration.... Agent: Lahive & Cockfield, LLP

20070093475 - Short-acting benzodiazepines: The present invention provides a compound of formula (I): wherein all variables are as defined herein, pharmaceutical formulations containing the same, processes for preparing the same and their use therapy.... Agent: Edwards & Angell, LLP

20070093477 - Alpha2c adrenoreceptor agonists: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070093476 - Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them: The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar1” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may... Agent: Milagros A Cepeda Reddy's Laboratories Inc

20070093479 - Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them: e

20070093478 - Novel mycobacterial inhibitors: is equal to 0 or 1 and R7 is hydrogen or Ar. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the... Agent: Philip S. Johnson Johnson & Johnson

20070093480 - Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors:

20070093481 - Benzopyran derivatives substituted with a thioxobenzoxazole derivative, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containingthem: The present invention relates to benzopyran derivatives substituted with a thioxobenzoxazole derivative, or pharmaceutically acceptable salts thereof, processes for preparing the same and a pharmaceutical composition containing the above as an effective ingredient Benzopyran derivatives substituted with thioxobenzoxazole derivatives, represented in <Formula 1>, have the function of protecting heart from... Agent: Lucas & Mercanti, LLP

20070093482 - Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors: The invention is also directed to a method for effecting the prophylaxis and therapy of degenerative joint diseases such as osteoarthroses, spondyloses, cartilage loss following joint trauma or a relatively long period of joint immobilization following meniscus or patella injuries or ligament ruptures, diseases of the connective tissue such as... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070093484 - 3-substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators: The present invention relates to 3-substituted-5,6-diarylpyrazine-2-carboxamide and -2-sulfonamide compounds and their compositions, processes for their preparation, and their use in the treatment of obesity and psychiatric and neurological disorders.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070093483 - Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo): There is disclosed the use of a compound of formula (I) wherein X, Y, W and Q are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070093486 - Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof: A process for preparing (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, pharmaceutically acceptable salts and solvates thereof such as the (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol hydrochloride salt via enzyme-catalyzed dynamic kinetic resolutions is provided.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070093487 - Novel polycyclic compounds which modulate ppargamma type receptors and cosmetic/pharmaceutical compositions comprised thereof: p

20070093485 - Substituted n-phenyl sulfonamide bradykinin antagonists: Disclosed are certain substituted N-phenylsulfonamide derivatives and related compounds. These compounds are useful as bradykinin antagonists to relieve adverse symptoms in mammals mediated, at least in part, by bradykinin including pain, inflammation, bronchoconstriction, cerebral edema, etc.... Agent: Foley & Lardner LLP

20070093488 - Novel benzothiazoles and the use thereof as medicaments: The invention especially relates to novel chemical compounds, especially novel benzothiazole derivatives, to compositions containing said compounds, and to the use thereof as medicaments.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070093489 - Phthalazinone derivatives: e

20070093490 - Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments: The invention relates to novel inhibitors of kinases, methods for preparing such inhibitors, intermediates for the preparation of such inhibitors and uses of such inhibitors.... Agent: Millen, White, Zelano & Branigan, P.C.

20070093494 - Novel compounds and their use related to compositions for treating disease: Novel compounds and their uses are disclosed herein.... Agent: Allergan, Inc. (t2-7h)

20070093491 - Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases: The invention provides novel condensed N-pyrazinyl-sulphonamides of formula (I) and their use in the treatment of chemokine mediated diseases.... Agent: Fish & Richardson P.C.

20070093492 - Pyrrolidine derivatives: Pyrrolidine compounds described herein and methods for using them to inhibit dipeptidyl peptidase IV or treat Type II diabetes.... Agent: Fish & Richardson PC

20070093493 - Treatment of benign prostatic hypertrophy and lower urinary tract symptoms: A method of treating symptoms of benign prostatic hypertrophy and a method of treating lower urinary tract symptoms, are disclosed. The method includes administering to a mammal about 1 to about 20 milligrams of an agent that inhibits cyclic guanosine 3,5-monophosphate specific phosphodiesterase type 5.... Agent: Marshall, Gerstein & Borun LLP

20070093496 - Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors: Hydroxy-substituted pyridopyrrolopyrazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I): (I) wherein a, b, A, B, R1, R2, R3, R4, R5, R6, R7 and R8 are defined herein. The compounds are useful in the prevention and... Agent: Merck And Co., Inc

20070093495 - Methods for treatment of parkinson's disease: New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070093497 - Methotrexate compliance packaging: The present invention provides a compliance system that contains at least one dispenser including at least one individual dose of an anti-folate therapeutic and at least one individual dose of a folic acid analog, each individual dose of anti-folate therapeutic and folic acid analog positioned in one or more individual... Agent: Townsend And Townsend And Crew, LLP

20070093498 - Thieno-pyrimidine compounds having fungicidal activity: The present invention relates to thieno[2,3-d]-pyrimidine compounds having fungicidal activity.... Agent: Dow Agrosciences LLC

20070093499 - Use of dasatinib for the treatment of bone metastasis: e

20070093500 - Substituted isoindole-1,3-diones: and pharmaceutically acceptable forms thereof, as α1a/α1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods... Agent: Philip S. Johnson Johnson & Johnson

20070093502 - 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication: d

20070093501 - Urea derivative, process for producing the same, and use:

20070093503 - Methods and kit for treating parkinson's disease: The efficacy of levodopa therapy in patients being treated for Parkinson's disease is enhanced by administering high doses of a partial glycine agonist. The frequency and severity of levodopa-induced side effects in Parkinson's disease patients are also reduced by administration of a partial glycine agonist.... Agent: Harness, Dickey, & Pierce, P.l.c

20070093504 - Salts of modulators of ppar and methods of treating metabolic disorders: Salt forms of potent modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.... Agent: International Patent Group Attn: Ms Lavern Hall

20070093505 - 2,3-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators: The present invention relates to 2,3-substituted-4,5-diarylpyrazine compounds and their compositions, processes for their preparation, and their use in the treatment of obesity and psychiatric and neurological disorders.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070093506 - Inhibitors of tyrosine kinases: wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy... Agent: Novartis Corporate Intellectual Property

20070093507 - Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives: The present invention relates to a fixed combination of a benzo[g]quinoline derivative and a prostaglandin derivative, and their use as pharmaceuticals, especially for treating glaucoma.... Agent: Novartis Corporate Intellectual Property

20070093508 - Non-basic melanin concentrating hormone receptor-1 antagonists: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for... Agent: Louis J. Wille Bristol-myers Squibb Company

20070093509 - Non-basic melanin concentrating hormone receptor-1 antagonists: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for... Agent: Louis J. Wille Bristol-myers Squibb Company

20070093510 - Phosphodiesterase 4 inhibitors: e

20070093511 - Anhydrous crystal form of valaciclovir hydrochloride: The invention relates to anhydrous crystalline valaciclovir hydrochloride, pharmaceutical compositions containing the same, its use in medical therapy and processes for preparing the same.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070093512 - Heterocyclic compounds: Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070093513 - Agent for repairing corneal perception: The present invention provides a novel pharmaceutical agent for recovering corneal sensitivity after corneal surgery and improving symptoms of dry eye. This pharmaceutical agent is useful for improving decreased corneal sensitivity and dry eye associated with corneal neurodegeneration such as post-cataract operation, post-LASIK operation, post-PRK operation, postkeratoplasty operation, neuroparalytic keratopathy,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070093514 - Therapeutic agent for keratoconjunctival disorder: An object of the present invention is to discover a new medicinal use of 5-[4-[[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]p henylmethyl]thiazolidine-2,4-dione and N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine. Both of the compounds exert an excellent improving effect on corneal disorder models and is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis, conjunctivitis,... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070093515 - Phosphodiesterase 10 inhibitors: Provided are certain quinazolines that are PDE10 inhibitors, pharmaceutical compositions, containing the same and processes for preparing the same. Also provided are methods of treating diseases treatable by PDE10 enzyme such as obesity, non-insulin dependent diabetes, schizophrenia or bipolar disorder, obsessive-compulsive disorder, and the like, by administering those certain quinazolines.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070093516 - Methods and formulations for modulating lyn kinase activity and treating related disorders: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in modulating lyn kinase activity. In particular, the compounds or a pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder... Agent: Cozen O'connor, P.C.

20070093517 - Local anesthetic compositions: The treatment of pain and related use by topical administration of an N-substituted-14-hydroxydihydronormorphine to a subject in need thereof. In some embodiments, the N-substituted-14-hydroxydihydronormorphine is nalbuphine.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070093519 - Anti-emetic uses of cannabinoid analogs: The present invention relates to non-psychoactive cannabinol analogs of tetrahydrocannabinol, (3R,4R)-Δ8—THC-11-oic acids, for treating and preventing nausea and relieving symptoms thereof.... Agent: Foley And Lardner LLP Suite 500

20070093518 - Pharmaceutical compositions for the treatment of organophosphate poisoning: A pharmaceutical composition comprising (i) a carbamate; (ii) a first anticholinergic; (iii) a second anticholinergic; and (iv) a pyridinium salt. The pharmaceutical composition is suitable for the treatment of organophosphate poisoning, including nerve agent and pesticide poisoning. The pharmaceutical composition provides an effective therapy against the lethal effects of nerve... Agent: Nixon & Vanderhye, PC

20070093520 - Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject: A method of treatment of diarrhea-predominant IBS in a subject, comprising administering to a subject in need of treatment a therapeutically effective amount of a composition comprising cilansetron or a pharmaceutically acceptable derivative thereof; and providing information that indicates that constipation, abdominal pain, upper respiratory tract infection and/or nausea may... Agent: Mayer, Brown, Rowe & Maw LLP

20070093521 - Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives: wherein X, A, B, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070093522 - Peptidomimetic ligands for cellular receptors and ion channels: One aspect of the present invention relates to novel peptidomometic compounds. A second aspect of the present invention relates to the use of the novel peptidomimetic compounds as ligands—agonists or antagonists—for various cellular receptors, e.g., G-protein-coupled receptors and opioid receptors, and various cellular ion channels, e.g., sodium and calcium. In... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070093523 - Tetrahydroisoquinoline lxr modulators: e

20070093524 - 5-lipoxygenase modulators: The present invention provides the use of Liver X Receptor (LXR) modulators that have been identified to downregulate 5-lipoxygenase gene expression in order to treat various diseases and disorders that involve the function of the 5-LO protein in intracellular signaling (or other cellular processes) or the function of protein products... Agent: Wilmerhale/wyeth

20070093525 - Triamide-substituted heterobicyclic compounds: e

20070093526 - 4-amino-piperidine derivatives as monoamine uptake inhibitors: The present invention provides compounds of formula (I) where n, R1, R2, R3, R4, R5 and Heteroaryl are defined herein. The compounds are inhibitors of the uptake of one or more monoamines selected from serotonin, norepinephrine and dopamine and, as such, may be useful in the treatment of disorders of... Agent: Eli Lilly & Company

20070093527 - Methods for treating disorders associated with hyperlipidemia in a mammal: The invention is directed to methods for treating hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitapide) and a HMG-CoA reductase inhibitor (for example simvastatin or atorvastatin). Co-administration of the MTP inhibitor with the HMG-CoA reductase inhibitor... Agent: Goodwin Procter LLP Patent Administrator

20070093528 - Pyridyltetrahydropyridines and pyridylpiperidines and method of manufacturing them: The present invention provides pyridine derivatives useful as intermediates of drugs and agricultural chemicals, electrophotographic receptors, dyes and so on. More specifically, the invention relates to novel pyridyltetrahydropyridines and novel pyridylpiperidines, and further to a method of manufacturing pyridine derivatives through reaction between bipyridine derivatives and benzyl halide or benzyloxycarbonyl... Agent: Sughrue Mion, PLLC

20070093529 - Diacylhydrazine derivatives: The present invention relates to diacylhydrazine derivatives of formula I, the use of the compounds of formula I as inhibitors of raf-kinase, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.... Agent: Millen, White, Zelano & Branigan, P.C.

20070093531 - Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them: The invention relates to substituted 4- or/and 7-hydroxyindoles, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active compounds for treating diseases which can be influenced by using the compounds according to... Agent: Fulbright & Jaworski L.L.P.

20070093530 - Substituted indolealkanoic acids: Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070093532 - Benzimidazole carboxamides as raf kinase inhibitors: The present invention relates to benzimidazole carboxamides of formula (I), the use of the compounds of formula (I) as inhibitors of as inhibitors of one or more kinases, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering... Agent: Heller Ehrman LLP

20070093533 - Crystalline s-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same: This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.... Agent: Sughrue Mion, PLLC

20070093534 - Modulation of pathogenicity: i

20070093535 - Vinyl phenyl derivatives as glk activators: The invention related to novel compounds of Formula (I) or a salt, solvate or prodrug thereof, wherein A, R1, R2, R3, n and m are as described in the specification, useful in the treatment of a disease or condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention... Agent: Morgan Lewis & Bockius LLP

20070093536 - Target protein of antidiabetic and novel antidiabetic insuful corresponding thereto: The present invention is intended to elucidate a molecular target of an antidiabetic such as a thiazolidine derivative. The present invention provides a screening method for an antidiabetic, comprising the steps of: bringing a candidate substance to be screened into contact with a protein represented by the following (a) or... Agent: Birch Stewart Kolasch & Birch

20070093537 - Thiazolyl-based compounds useful as kinase inhibitors: useful for treating p38 kinase-associated conditions, wherein ring A is phenyl or pyridyl, and X, Y, B, R2, R3, Z1 m and n are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and... Agent: Louis J. Wille Bristol-myers Squibb Company

20070093538 - Preparation for the fungicidal and algicidal finish of alkaline coating compositions: The invention relates to a preservative comprising at least one isothiazolone, at least one quaternary ammonium compound, and at least one stabilizer selected from the group of sulphite salts, hydrogen sulphite salts, sulphite-releasing compounds and hydrogen-sulphite-releasing compounds, the presence of algicidal triazine being ruled out. The preservative inhibits the growth... Agent: Linda K. Russell

20070093539 - N-hydroxy-4-(3-pheyl-5-methyl-isoxazole-4-yl)-benzenesulfonate solvates: [solvate] represents water, C1-C4 alcohol, C1-C4 alkylester of C1-C3 carboxylic acid or dioxane, and the mixture of solvated (wherein n=1) and solvat-free forms (wherein n=0). Furthermore, the invention relates their process for production and use for the treatment of osteoarthritis and rheumatoid arthritis and surgical and primary dysmenorrheal pains, based... Agent: The Firm Of Karl F Ross

20070093540 - process for the preparation of angiotensin ii antagonistic compounds: A process for the preparation of angiotensin II antagonists and novel intermediates useful for the synthesis thereof.... Agent: Griffin & Szipl, PC

20070093541 - Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors: The invention relates to a method of treatment of dementia and/or regression of cognitive function, comprising co-administration of effective amounts of an Angiotensin II antagonist and an Angiotensin I Converting Enzyme inhibitor, pharmaceutical compositions containing an Angiotensin II antagonist together with an ACE inhibitor and the use of an Angiotensin... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070093542 - Process for the preparation of valsartan and intermediates thereof: Provided are process for the preparation of valsartan and the precursors thereof.... Agent: Kenyon & Kenyon LLP

20070093543 - Fungicidal mixtures based on carbamate derivatives and insecticides: The present invention relates to mixtures comprising as active components a) carbamate derivatives of the formula (I) in which the substituents and the index have the following meaning: T is CH or N n is 0, 1 or 2 R is halogen, C1-C4-alkyl or C1-C4-haloalkyl, it being possible for the... Agent: Hutchison Law Group PLLC

20070093544 - Benzamidazoles, compositions containing such compounds and methods of use: The present invention relates to substituted benzimidazoles, compositions containing such compounds and methods of treatment The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.... Agent: Merck And Co., Inc

20070093545 - 4-oxo-4,5-dihydro-furan-2-carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof: System for selecting a colour shade comprising a very small number of colour display cards with mixed shades of two or more colours. The system comprises means for selecting one shade among mixed shades, means for presenting the selected mixed shade as well as means for specifying the selected mixed... Agent: Arena Pharmaceuticals, Inc.

20070093546 - Use of rotigotine for the treatment of depression: The present invention relates to the use of rotigotine [(−)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol] and its prodrugs and pharmaceutically acceptable salts for producing a pharmaceutical agent for treating depression.... Agent: Harness, Dickey, & Pierce, P.l.c

20070093547 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20070093548 - Use of progesterone receptor modulators:

20070093549 - Methods for preparation of ladostigil tartrate crystalline form a1: Provided are processes for preparing crystalline ladostigil tartrate form A1.... Agent: Kenyon & Kenyon LLP

20070093550 - Method and compound for the prophylaxis or treatment of an immunodeficiency condition, such as aids: A method and compound for the prophylaxis or treatment of an immunodeficiency condition, such as acquired immunodeficiency syndrome (AIDS) includes a glycol derivative. More specifically, the glycol derivative includes diethylene glycol dibenzoate.... Agent: Dinesh Agarwal, P.C.

20070093551 - Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites: A composition and method for producing a beneficial effect on a subject's nerve associated with at least one of a cosmetic condition, a dermatological indication and a dental indication and another condition. The composition comprises a hydroxy-oligocarboxylic ester and is formulated for topical administration of the product to a subject... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070093552 - Early insulin secretion stimulator: The invention provides an early insulin secretion stimulator consisting of corosolic acid, etc. The early insulin secretion stimulator of the invention is capable of rapidly inducing secretion of insulin immediately after meals without inducing secretion of excess insulin in the absence of blood glucose increase.... Agent: Morgan Lewis & Bockius LLP

20070093553 - Hmb compositions and uses thereof: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixtures thereof. HMB may be added... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1

20070093554 - Agent for improving feeling of cold: It is desirable to provide a medicament or nutritional food to improve feeling of cold and to create fulfilling life for people who are suffering from feeling of cold. Specifically, one object of the present invention is to provide an, agent, a food and drink, or a food additive which... Agent: Darby & Darby P.C.

20070093555 - Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same: Topical pain relief compositions of N,2,3-trimethyl-2-isopropylbutamide and methods for using the same are provided. The subject compositions include a pain relieving effective amount of N,2,3-trimethyl-2-isopropylbutamide in a topical formulation, e.g., a patch, gel, cream or foam. Also provided are methods of using the subject compositions in pain relief applications.... Agent: Bozicevic, Field & Francis LLP

20070093556 - Toremifene crystallization method: The invention relates to a method for isolating toremifene from a mixture of toremifene and its corresponding E isomer. The method comprises contacting the isomer mixture with a first solvent comprising methanol, allowing toremifene to crystallize in said first solvent, allowing the crystallized product of the previous step to crystallize... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070093557 - Sertraline hydrochloride form ii and methods for the preparation thereof: The present invention is directed to Form II of sertraline hydrochloride and novel methods for its preparation. According to the present invention, sertraline hydrochloride Form II may be produced directly form sertraline base or sertraline mandelate. It may also be produced from sertraline hydrochloride solvate and hydrate forms, and crystallized... Agent: Steven J. Lee Kenyon & Kenyon

20070087958 - Compounds and compositions for delivering active agents: Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.... Agent: Darby & Darby P.C.

20070087957 - Methods and compositions for oral administration of proteins: This invention provides compositions comprising a protein and an omega-3 fatty acid, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.... Agent: Pearl Cohen Zedek Latzer, LLP

20070087959 - Method of inducing biomineralization method of inducing bone regeneration and methods related thereof: A method of inducing biomineralization in a tissue, which method comprises administering to the tissue a source of Phosphophoryn (PP) in an amount sufficient to induce biomineralization; a method of treating tooth sensitivity or injured pulp tissue; a method of inducing differentiation of a cell into an osteogenic cell or... Agent: Leydig Voit & Mayer, Ltd

20070087961 - Conjugates of hydroxyalkyl starch and erythropoietin: Conjugates of hydroxyethyl starch and erythropoietin are provided. The conjugates comprise a linking compound that is covalently linked to erythropoietin and covalently linked to hydroxyethyl starch. Methods of producing the conjugates, and their use, also are provided.... Agent: Fish & Richardson P.C.

20070087960 - Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are... Agent: King & Spalding LLP

20070087962 - Pharmaceutical compositions comprising cyclosporins: A liquid comprising a therapeutically effective concentration of a cyclosporin and a vitamin E tocopherol polyethylene glycol succinate, wherein said liquid is an emulsion. is disclosed herein. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein.... Agent: Brent A. Johnson Allergan, Inc.

20070087963 - Synthesis of cyclosporin analogs: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis... Agent: Fish & Richardson P.C.

20070087967 - Methods and compositions for inhibiting angiogenesis: The present invention provides a method of inhibiting angiogenesis within a tissue by providing exogenous PEDF to cells associated with the tissue. The presence of exogenous PEDF inhibits angiogenesis within the tissue, in part by interfering with the ability of vascular endothelia to expand within the tissue. The invention also... Agent: Morgan, Lewis & Bockius LLP

20070087968 - Methods to treat t-cell disorders using tisf: T4 Immune Stimulating Factor (TISF) selectively induces aberrant T-cells to initiate apoptosis. TISF and peptides that are related to TISF (TISF peptides) are therefore useful for the treatment of disorders characterized by aberrant production, development, or activity of T-cells or other cells of hematopoietic origin. This invention relates to methods... Agent: Morrison & Foerster LLP

20070087964 - Novel compositions and methods for modulating the acid-sensing ion channel (asic): Novel compositions for modulating acid-sensing ion channels (ASIC) function comprising ASICα, ASICβ, and BNC1 and derivatives thereof; methods for modulating ASIC function and methods for treating cognitive disorders and for memory enhancement using the novel compositions of the invention; and a method for increasing synaptic plasticity are described.... Agent: Mckee, Voorhees & Sease, P.L.C

20070087966 - Prolactin and chronic and acute pain disorders: The embodiments disclosed herein provide methods for inhibiting, reducing and/or treating pain in a subject by administering to a subject in need thereof a pharmaceutical formulation that includes a pharmacologically active compound that is adapted to disrupt PRL signaling in pain neurons. In certain embodiments, the compound is a PRL-R... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20070087965 - Treatment of psoriasis through down-regulation of the egf-receptor with topically applied egf: From unrelated but similar fields it is deduced that certain forms of psoriasis can be effectively treated through topical application of EGF-containing formulations. This patent application summarizes the theoretical basis for this finding and requests protection for the idea, while clinical evaluation is in preparation.... Agent: Bell, Boyd, & Lloyd LLP

20070087970 - Use of c-reactive protein to treat immune complex-mediated renal disease: The present invention relates to a method of treating or preventing kidney disease in an animal subject including administering an effective amount of C-reactive protein to the animal subject. The kidney disease may be associated with systemic lupus erythematosus.... Agent: Henry D. Coleman

20070087969 - Wound healing and treatment of fibrosis: Compositions for use in the treatment of wounds and fibrosis comprising a therapeutically effective amount of a compound that modulates actin assembly and organization intracellularly and/or extracellularly and a pharmaceutically acceptable vehicle; such a compound promotes the rate of wound healing and also prevents or reduces fibrosis. A preferred compound... Agent: Nixon & Vanderhye, PC

20070087971 - Peptides, derivatives and analogs thereof, and methods of using same: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment... Agent: Pepper Hamilton LLP

20070087972 - Prion-specific peptoid reagents: The invention relates to peptoid reagents that interact preferentially with a pathogenic form of a conformational disease protein as compared to a nonpathogenic form of the conformational disease protein where the peptoid reagent comprises an amino-terminal region, a carboxy-terminal region, and at least one peptoid region between the amino-terminal region... Agent: Novartis Vaccines And Diagnostics Inc.

20070087973 - Processes and intermediates: The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.... Agent: Miller Canfield Paddock And Stone PLC

20070087974 - Treatment or prevention of respiratory viral infections with immunomodulator compounds: An immunomodulatory compound is administered to a patient having, or at risk of a respiratory viral infection.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070087975 - Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients: Is described a method of treating left ventricular hypertrophy comprising administering an effective amount of propionyl L-carnitine, or a pharmaceutical salt thereof, to ESRD or dialysed patients in need of such treatment.... Agent: Nixon & Vanderhye, PC

20070087978 - Method of controlling animal pests: A method of treating plant and animal systems and inanimate surfaces for the purposes of controlling plant pests, introducing pesticides and nutrients into plants, mitigating frost damage to plants, increasing crop yields, controlling certain plant diseases, controlling arthropod, bacterial, fungal, mycoplasma, rickettsia, and viral pests of animals and humans, and... Agent: Craig Gregersen Law Offices Of Craig Gregersen

20070087977 - Methods and compositions for treating pain: Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular,... Agent: Wilson Sonsini Goodrich & Rosati

20070087976 - Topiramate and pharmaceutical formulations thereof: As demonstrated herein, topiramate can be rendered substantially non-hygroscopic if present in a particularly pure form and with a small particle size. Accordingly, the present invention relates to a highly pure form of topiramate, having a particle size of ≦250 μm, and pharmaceutical formulations which contain this active substance.... Agent: Smith Patent Consulting Consulting, LLC

20070087979 - Sulfatides for treatment of autoimmune disorders: Disclosed herein are methods for the treatment of autoimmune or immune related diseases or disorders. Also disclosed are methods for treating such autoimmune or immune related diseases or disorders with the administration of sulfatides. Also disclosed herein are methods of treating autoimmune or immune related diseases or disorders by administering... Agent: Knobbe Martens Olson & Bear LLP

20070087980 - azithromycin-containing aqueous pharmaceutical composition and a method for the preparation of the same: The invention provides an azithromycin-containing aqueous pharmaceutical composition, which comprises at least one member selected from the group consisting of azithromycin, its anhydride, its hydrate, and pharmaceutically acceptable salts thereof, and at least one member selected from the group consisting of monoethanolamine, diethanolamine, triethanolamine, amino acid, ethylenediaminetetraacetic acid, and pharmaceutically... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070087981 - Water soluble and palatable complexes: The products and methods of the present invention provide a means for increasing the solubility and bioavailability of active agents. More particularly the invention provides compositions containing active agents as water-soluble complexes with glycyrrhizin, and methods of preparing such complexes. The invention further provides methods for the preparation of highly... Agent: Lucas & Mercanti, LLP

20070087992 - Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof: A gene that is a positive mediator of tumor growth and metastasis in certain cancer types is provided. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of SCC-S2 such as renal, ovarian, head and neck, breast, prostate, brain, chronic myelogenous... Agent: Ip Group Of Dla Piper US LLP

20070087990 - Cc chemokine receptor 5 dna, new animal models and therapeutic agents for hiv infection: The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step... Agent: Klarquist Sparkman, LLP

20070087986 - Compositions and methods for enhancing immunity by chemoattractant adjuvants: The invention is directed to methods and compositions for enhancing immunity, including mucosal immunity. The compositions include an antigen or immunogen, a ligand for a Toll-like receptor and at least one chemoattractant.... Agent: Magdalena O. Cilella Brinks Hofer Gilson & Lione

20070087988 - Hematopoietic progenitor kinase 1 for modulation of an immune response: Methods of regulating hematopoietic progenitor kinase 1 (HPK1) are described as are methods of identifying compounds that can regulate HPK1.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070087984 - Method of identifying agents that inhibit the growth of cancer cells: The present invention is directed to methods of identifying agents useful for inhibiting cancer cells. The agents bind to one of the proteins described herein, or to a gene or mRNA encoding such protein. The invention is also directed to methods for inhibiting cancer cells by administering an agent that... Agent: Law Office Of David Spolter G Singer

20070087989 - Methods of treating ocular conditions: The present invention provides siRNA specific for myocilin and mutant myocilin, and methods of treating ocular conditions and/or diseases.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070087982 - Methods of treatment and diagnosis using modulators of virus-induced cellular gene sequences: Applicants have used microarrays, gene expression profiling, and gene silencing methods to identify and provide a plurality of ‘validated’ virus-induced cellular gene sequences (e.g., HMG20B, HRH1, NP and c-YES (src family kinases)) and pathways useful as therapeutic targets for modulation of viral-mediated cellular effects. Particular embodiments provide therapeutic compositions, and... Agent: Klarquist Sparkman, LLP

20070087987 - Modulation of glucagon receptor expression: Compounds, compositions and methods are provided for modulating the expression of glucagon receptor. The compositions comprise antisense compounds, particularly antisense oligonucleotides which have particular in vivo properties, targeted to nucleic acids encoding glucagon receptor. Methods of using these compounds for modulation of glucagon receptor expression and for treatment of diseases... Agent: Elmore Patent Law Group

20070087985 - Mrck-related compositions and methods: This invention provides a composition comprising a pharmaceutically acceptable carrier and a nucleic acid which, when introduced into a cell wherein MRCK is expressed, inhibits the expression of MRCK in the cell. This invention further provides a method for identifying an agent that inhibits MRCK expression in a cell. This... Agent: Cooper & Dunham, LLP

20070087983 - Novel ubp8rp polypeptides and their use in the treatment of psoriasis: The invention encompasses a novel gene encoding a protein of the ubiquitin-proteasome pathway, UBP8rp. The invention also relates the use of UBP8rp polypeptides for screening for modulators, and to the use of said modulators for treating chronic inflammatory diseases such as, e.g., psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070087991 - Pluripotential stem cells: We describe a method to manipulate the phenotype of stem cells, preferably pluripotential stem cells including nucleic acids and vectors used in said methods.... Agent: Crowell & Moring LLP Intellectual Property Group

20070087993 - Method for transdifferentiation of body tissues: The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune diseases.... Agent: Darby & Darby P.C.

20070087994 - A1 adenosine receptor agonists: Disclosed are novel compounds that are A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, diseases related to release of nonesterified fatty acids, and myocardial infarction.... Agent: Cv Therapeutics, Inc

20070087995 - Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis b: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The... Agent: King & Spalding LLP

20070087996 - Method of extracting fucoidan: A method of extracting fucoidan from a biological material is provided. The method comprises (a) combining a biological material containing fucoidan and a medium to form a mixture; (b) applying ultrasonic waves to the mixture while the mixture is at a temperature of less than about 60 C; (c) extracting... Agent: The Maxham Firm

20070087997 - Methods for producing modified microcrystalline chitosan and uses therefor: Disclosed are methods of producing modified microcrystalline chitosan. Chitosan in aqueous solution is degraded enzymatically, hydrolytically or oxidatively. The chitosan solution is then alkalized with agitation using aqueous hydroxides and/or their salts to attain a pH not lower than 7.0. The precipitated modified microcrystalline chitosan is highly pure and may... Agent: Dykema Gossett PLLC

20070088000 - Beta-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases: Methods of reducing the risk of transmission of a sexually transmitted pathogen by contacting the pathogen or cells susceptible to infection by the pathogen with a β-cyclodextrin are provided. Methods for reducing the risk of transmission of a sexually transmitted pathogen to or from a subject by contacting the pathogen... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20070087998 - Imidazole compounds that modulate hsp90 activity: Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070087999 - Pharmaceutical compositions containing cyclodextrins and taxoids: The present invention relates to water-soluble solid pharmaceutical compositions and their solutions in aqueous solvents, said compositions containing a) as an active ingredient a finely dispersed large surface area amorphous preferably lyophilized taxoid such as paclitaxel or docetaxel, their salts or their polymorphic hydrates or solvates such as solvates formed... Agent: Davidson, Davidson & Kappel, LLC

20070088001 - Silinane compounds as cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Berlex Biosciences Patent Department

20070088002 - Orally available sphingosine 1-phosphate receptor agonists and antagonists: The present invention relates to S1P analogs that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure (I) wherein R11 is C5-C18 alkyl or C5-C18 alkenyl; Q is selected from the... Agent: University Of Virginia Patent Foundation

20070088003 - Asthma associated factors as targets for treating atopic allergies including asthma and related disorders: This invention relates to methods for treating asthma or allergy in a mammal by administering a 3-aminosteroid compound to a mammal in need thereof. The 3-aminosteroid compound being capable of down regulating the IL-9 pathway and alleviating asthmatic responses to allergen. Exemplary 3-aminosteroid compounds used in the methods of the... Agent: Morgan Lewis & Bockius LLP

20070088004 - Mao-b inhibitors useful for treating obesity: i

20070088005 - Pharmaceutical compositions for headache, migraine, nausea and emesis: S-alkylsiothiouronium derivatives such as S-ethylisothiouronium diethylphosphate are used for the treatment of headaches, in particular, migraines, as well as for the prevention or treatment of nausea and vomiting. The compositions of the invention are also effective in preventing or alleviating emesis associated with migraines or other medical conditions such as... Agent: Winston & Strawn LLP Patent Department

20070088006 - Preemptive prophylaxis of migraine: A method of preventing the headache phase of migraine in a human comprises administration of a 5HT1 receptor agonist or administration of an over-the-counter or nonprescription drug to said human exhibiting prodrome symptoms of migraine. Suitably, the method comprises administration of a migraine headache phase-preventing effective amount of the 5HT1... Agent: Husch & Eppenberger, LLC

20070088008 - 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds: Biologically active 19-nor vitamin D analogs substituted at C-2 in the A-ring with an ethylidene or an ethyl group. These compounds have preferential activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity which allows their in vivo administration for the treatment of metabolic bone... Agent: Andrus, Sceales, Starke & Sawall, LLP

20070088007 - Method for preparing analogue of vitamin d: A method for preparing analogues of C1,C24-dihydroxy-vitamin D is disclosed. Especially the method for preparing calcipotriol and tacalcitol from a starting material of Vitamin D2 is disclosed here. Calcipotriol (compound 1(a)) and tacalcitol (compound 1(b)) can be synthesized by the method of the present invention. Moreover, only nine steps are... Agent: Lowe Hauptman Berner, LLP

20070088009 - Triterpene quaternary salts as biologically active surfactants: The invention provides novel compounds that are quaternary amine derivatives of betulin and other triterpenes. The compounds have antibacterial, antifungal, and surfactant properties.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070088011 - Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same: The multiphase combination preparation for oral therapy of dysfunctional uterine bleeding and for oral contraception contains a first phase of 2 daily dosage units, each consisting of 3 mg of estradiol valerate; a second phase of two groups of daily dosage units, which consist of a first group containing 5... Agent: Striker, Striker & Stenby

20070088010 - Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest: The single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding contains at least 21 separately packaged and individual administered daily dosage units in a single container. Each orally administered daily dosage unit contains a combination of ethinyl estradiol and dienogest in low dosage. Administration of this preparation results in... Agent: Michael J. Striker

20070088012 - Method of treating or preventing type-2 diabetes: The present invention is generally related to a method of treating, preventing, or reducing the risk of developing type-2 diabetes, and, more particularly, is related to a method of administering a transdermal hydroalcoholic gel composition to treat or prevent type-2 diabetes and a method of administering a transdermal hydroalcoholic gel... Agent: Mayer, Brown, Rowe & Maw LLP

20070088013 - (s)-6-methyloxaalkyl exemestane compounds and related methods of use: 6-Methyloxaalkyl exemestane compounds and related compositions, as can be used, chemotherapeutically, to inhibit growth and proliferation of cancer cells.... Agent: Reinhart Boerner Van Deuren S.c. Attn: Linda Kasulke, Docket Coordinator

20070088014 - Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present... Agent: Stephen Donovan Allergan, Inc.

20070088015 - Non-nucleoside reverse transcriptase inhibitors: The present invention provides for compounds useful for treating an HIV-1 infection, or preventing an HIV-1 infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, R5 and X are as herein defined. Also disclosed in the present invention are... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070088016 - Tricyclic steroid hormone nuclear receptor modulators: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or... Agent: Eli Lilly & Company

20070088017 - Benzothiazole derivatives for the treatment of diabetes: The present invention is related to the use of benzothiazole derivatives for the manufacture of a medicament for the treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary syndrome (PCOS) Formula (I). G is an unsubstituted or... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070088018 - Cb1 antagonist compounds: Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis,... Agent: Eli Lilly & Company

20070088020 - 2-imino-1,3-thiazine derivatives: The present invention relates to 2-imino-1,3-thiazine derivatives, in specific, 2-imino-1,3-thiazine derivatives having a selective antagonistic activity or agonistic activity to a cannabinoid type 2 receptor and their pharmaceutical use.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070088019 - Macroheterocyclic compounds as kinase inhibitors: This invention is directed to macroheterocyclic compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disease, condition or disorder.... Agent: Philip S. Johnson Johnson & Johnson

20070088021 - 4-haloisoquinoline derivative and drug containing the same: i

20070088022 - Tetrahydroquinolines, synthesis thereof, and intermediates thereto: The present invention relates to methods for synthesizing compounds useful as 5HT2C agonists or partial agonists, derivatives thereof, and to intermediates thereto.... Agent: Choate, Hall & Stewart LLP

20070088023 - Method of administration for 5-(2-chlorophenyl)-1,2-dihydro-7-fluoro-8-methoxy-3-methyl-oyrazolo[1,4]benzodiazepine: The invention relates to improved methods of administration of 5-(2-chlorophenyl)-1, 2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine in the treatment of cancer, such as breast, colon, lung, and prostate cancer. In particular, the invention relates to a method of treating cancer by administering the above compound or a therapeutically effective salt or ester thereof in an... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070088024 - Active substance combination comprising a carbinol combined to at least an nsaid: The present invention relates to an active substance combination comprising at least one substituted carbinol compound and at least one non-steroidal anti-inflammatory drug (NSAID), a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination for the manufacture of a medicament.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070088025 - Tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivatives as cannabinoid cb1 receptor agonists: The invention relates to tricyclic 1-[(in-dol-3-yl)carbonyl]piperazine derivative having the general Formula (I) wherein X is CH2, O or S; R represents 1-3 substituents independently selected from H, (C1-4)alkyl, (C1-4)alkyloxy and halogen; R1 is (C5-8)cycloalkyl; R2 is H or (C1-4)alkyl; R3, R3′, R4′, R4′, R5, R5′ and R6′ are independently hydrogen... Agent: Akzo Nobel Inc.

20070088026 - 5-phenylpyrimidines, their preparation, intermediates for their preparation, and their use for controlling harmful fungi: e

20070088027 - Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient: Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and/or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula... Agent: Sughrue-265550

20070088028 - 17-acetamido-4-azasteroid derivatives as androgen receptor modulators: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis,... Agent: Merck And Co., Inc

20070088029 - Tricycloundecane compounds useful as modulators of nuclear hormone receptor function: Tricycloundecanes compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds are disclosed.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070088030 - Aerosol formulations for the inhalation of beta-agonists: (b) a second active substance 2 selected from tiotropium salts, oxitropium salts, flutropium salts, ipratropium salts, glycopyrronium salts, and trospium salts, or a tautomer, enantiomer, solvate, or hydrate thereof; (c) at least one pharmacologically acceptable acid; and (d) a solvent selected from water, ethanol, or a mixture of water and... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070088031 - Novel chemical compounds: The present invention relates generally to inhibitors of the kinases, such as GSK-3, and more particularly to fused pyrimidine compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070088032 - Processes for the preparation of benzoimidazole derivatives: e

20070088033 - Diaryl substituted pyridinones: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using... Agent: Pharmacia Corporation Global Patent Department

20070088034 - Oxo-substituted cyclohexyl-1,4-diamine compounds: d

20070088035 - Crystalline forms of [(1r), 2s]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester: Crystalline form, Form N-1, of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester (Compound I) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising the Form N-1 of Compound I as well as a method of using the Form N-1 of Compound I in the treatment of cancer... Agent: Louis J. Wille Bristol-myers Squibb Company

20070088038 - 2-amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions: y

20070088037 - Novel imidazole compounds as transforming growth factor (tgf) inhibitors: Novel imidazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)- signaling pathway. They are useful in the treatment of various TGF-related disease states... Agent: Warner-lambert Company

20070088036 - Piperidine derivatives and methods of use: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1... Agent: Townsend And Townsend And Crew, LLP

20070088039 - Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function: and/or pharmaceutically-acceptable salts thereof, useful in the treatment of androgen-receptor associated conditions, wherein Ar is aryl, substituted aryl, heteroaryl, or substituted heteroaryl; L is a linker as defined in the specification; R1 may be hydrogen, cyano, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclo, substituted heterocyclo, heteroaryl, or... Agent: Louis J. Wille Bristol-myers Squibb Company

20070088040 - Antibacterial compounds: d

20070088041 - Pyridazinone derivatives, methods for their production and their use as pharmaceuticals:

20070088042 - Fluorinated 4-azasteroid derivatives as androgen receptor modulators: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient.... Agent: Merck And Co., Inc

20070088043 - Novel hdac inhibitors: The present invention relates to novel compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions. The present invention more particularly provides novel HDAC inhibitors of the general formula (1). Also included is a method for treatment of cancer, psoriasis,... Agent: Oliff & Berridge, PLC

20070088044 - Quinazoline derivatives as antitumor agents: The invention concerns quinazoline derivatives of Formula (I); wherein each of Q<1>, Q<2>, Z, R<1>, R<2>, R<3>, and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention... Agent: Morgan Lewis & Bockius LLP

20070088045 - Histone deacetylase inhibitors for treating degenerative diseases of the eye: Compositions and methods for treating degenerative conditions and diseases of the eye with histone deacetylase inhibitors are disclosed.... Agent: Alcon Research

20070088046 - Derivatives of 14.15-dihydro 20.21-dinoreburnamenin-14-ol, and applications thereof: in which R represents a radical —AR′ wherein A represents a heteroatom and R′ represents a group selected from the group comprising linear or branched C1-C6 alkyl radicals, C2-C6 alkenyls, C2-C6 alkynyls, arylalkyls; esters comprising the formula —R1— CO—O—R2; amides comprising the formula —R3—CO—NZY, wherein Y and Z together can... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070088047 - 21-heterocyclic-4-azasteroid derivatives as androgen receptor modulators: Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient.... Agent: Merck And Co., Inc

20070088048 - Clopidogrel salt and polymorphic forms thereof: The invention relates to methyl(+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-C]pyridine-5(4H) acetate naphthalene-1,5-disulfonate or a polymorphic form and/or a hydrate and/or a solvate thereof, to pharmaceutical compositions containing the same, and to the method of use thereof for inhibiting platelet aggregation.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070088049 - Polymorphic forms of methyl (+)-(s) - alpha - (2-chlorophenyl)-6, 7-dihydrothieno [3,2-c]pyridine-5(4h) acetate hydrobromide, clopidogrel hydrobromide: The invention relates to polymorphic Forms B, C, and D of methyl(+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-C]pyridine-5(4H) acetate hydrobromide, to pharmaceutical compositions containing the same, and to the method of use thereof for inhibiting platelet aggregation.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070088050 - Crystals of laquinimod sodium, and process for the manufacture thereof: Disclosed is a process for the preparation of laquinimod sodium which removes the impurities after the salt formation step, thus resulting in crystals of higher purity as well as crystals having improved crystalline characteristics.... Agent: Cooper & Dunham, LLP

20070088051 - Indolinones and their use as antiproliferative agents: s

20070088054 - Biphenyl derivatives: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl... Agent: Theravance, Inc.

20070088053 - Non-nucleoside reverse transcriptase inhibitors: The present invention provides for compounds useful for treating an HIV-1 infection, or preventing an HIV-1 infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1-R4 and Ar are as herein defined. Also disclosed in the present invention are methods of treating an... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070088052 - Sulfonamide derivatives as 5ht7 receptor antagonists: The present invention discloses a compound of formula (I):—wherein A is an aromatic moiety or selected from benzyl, C1-C16 alkyl dialkylamino, dialkylaminoalkyl, alkoxyalkyl, cyano, and mono-, di-, or tri-hydroxyalkyl and/or aryl, B is an aromatic moiety, R1 and R2 are independently C1 to C6 alkyl or NR1R2 forms a 5... Agent: Fish & Richardson P.C.

20070088055 - Process for producing 1-benzyl-4-[ (5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine or hydrochloride thereof: 1-Benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine or hydrochloride thereof, which is useful as a drug, can be produced in high purity by safer and easier operations suitable for industrial production by subjecting 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-ylidene]methyl-piperidine or a solvate thereof to catalytic hydrogenation in the presence of a palladium-alumina catalyst and if necessary, converting the thus obtained compound... Agent: Birch Stewart Kolasch & Birch

20070088056 - Use of a pyrazole derivative for producing medicaments that are useful in preventing and treating chronic bronchitis and chronic obstructive bronchopneumopathy: The present invention relates to a method for treating or preventing chronic bronchitis and chronic obstructive pulmonary disease, and also the chronic bronchitis associated with chronic pulmonary disease in a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of the pyrazole-derived compound that is an... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070088057 - Bis(thio-hydrazide amide) formulation: 2 g of which is reconstitutable in 10 mL of a water in less than 10 minutes, and methods for preparing these compositions. Also disclosed are compositions comprising a compound represented by structural formula (I) and a pharmaceutically acceptable excipient, wherein the molar ratio of said compound to said excipient... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070088058 - Aralkyl amines as cannabinoid receptor modulators: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck And Co., Inc

20070088059 - Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides: This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems. Formula I:... Agent: Elmore Patent Law Group, PC

20070088060 - new effector conjugates, process for their production and their pharmaceutical use: Conjugates of epothilones and epothilone derivatives (as effectors) with suitable biomolecules (as recognition units) are described. Their production is carried out by the effectors being reacted with suitable linkers, and the compounds that are produced are conjugated to the recognition units. The pharmaceutical use of the conjugates for treating proliferative... Agent: Millen, White, Zelano & Branigan, P.C.

20070088062 - N-[4-(heteroarylmethyl)phenyl]-heteroarylamines: n

20070088061 - New 3-phenylpropionic acid derivatives: The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or... Agent: Darby & Darby P.C.

20070088063 - Gamma-secretase inhibitors: e

20070088064 - Pharmaceutical composition containing bicyclic type compounds:

20070088065 - Metaxalone products, method of manufacture, and method of use: Disclosed herein is a method of using metaxalone. In one embodiment, the method comprises obtaining metaxalone from a container providing information that metaxalone affects the activity of a cytochrome p450 isozyme. In another embodiment, the method comprises informing a user that metaxalone affects the activity of a cytochrome p450 isozyme.... Agent: Cantor Colburn, LLP

20070088066 - Metaxalone products, method of manufacture, and method of use: Disclosed herein is a method of using metaxalone. In one embodiment, the method comprises obtaining metaxalone from a container providing information that metaxalone affects the activity of a cytochrome p450 isozyme. In another embodiment, the method comprises informing a user that metaxalone affects the activity of a cytochrome p450 isozyme.... Agent: Cantor Colburn, LLP

20070088067 - Novel amidine compounds for treating microbial infections: Novel amidine and diamidine compounds are useful in the treatment of microbial infections, including mycobacterial, fungal and protozoal infections. Pharmaceutical formulations comprising these compounds can be used in methods of treating microbial infections.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070088068 - Benzo[f]isoindole derivatives with affinity to the ep4 receptor: v

20070088069 - Novel imidazoles: Novel imidazole compounds and pharmaceutical compositions are described, as are methods of using such compounds, alone or in combination with another pharmaceutically active agent, to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and atherosclerosis.... Agent: Warner-lambert Company

20070088070 - Pyrazole derivatives, compositions containing such compounds and methods of use: Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... Agent: Merck And Co., Inc

20070088071 - Acyl indoles, compositions containing such compounds and methods of use: The present invention relates to substituted indoles, compositions containing such compounds and methods of treatment The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus and related conditions.... Agent: Merck And Co., Inc

20070088074 - Article of manufacture comprising aromatic amino acids isomers, analogs, or derivatives thereof to treat neurological disorders involving dysfunction of glutamatergic synaptic transmission: Disclosed herein are articles of manufacture that comprise compositions comprising one or more aromatic amino acids, analogs or isomers thereof, and/or combinations thereof. The articles of manufacture are useful for treatment of neurological conditions related to or which can be affected by, modulation of glutamate receptor (GluR) activity.... Agent: Beusse Wolter Sanks Mora & Maire

20070088072 - Method for treating pain: s

20070088073 - Method for treating pain:

20070088075 - Deuterated aminocyclohexyl ether compounds and processes for preparing same: This invention is directed to deuterated aminocyclohexyl ether compounds and processes for preparing same and methods of using same.... Agent: Seed Intellectual Property Law Group PLLC

20070088076 - Taxoid-fatty acid conjugates and pharmaceutical compositions thereof: The invention relates to a second-generation-fatty acid conjugate and pharmaceutical compositions thereof. The second-generation-fatty acid conjugate are useful in the treatment of cancer in a human in need thereof.... Agent: Ronald J. Baron Hoffmann & Baron

20070088077 - Appetite stimulation and reduction of weight loss in patients suffering from symptomatic hiv infection: Patients with symptomatic HIV infection, including AIDS and ARC are treated to increase appetite and to cause a reduction in loss of weight. The delta-9-tetrahydrocannabinol may be administered orally, in capsules, or in tablets, or by injection, suppository, intranasal, transdermal, inhalant or sublingual administration.... Agent: Joseph A. Mahoney Mayer, Brown & Platt

20070088078 - Methods for managing adipocyte fat accumulation: The present invention provides methods for management fat accumulation in an adipocyte using compositions comprising a polymethoxylated flavone fraction of at least one of 5,6,7,3′,4′-pentamethoxyflavone (sinensetin); 5,6,7,8,3′,4′-hexamethoxyflavone (nobiletin); 5,6,7,8,4′-pentamethoxyflavone (tangeretin); 5-hydroxy-6,7,8,3′,4′-pentamethoxyflavone (auranetin); 5-hydroxy-7,8,3′,4′-tetramethoxyflavone; 5,7-dihydroxy-6,8,3′,4′-tetramethoxyflavone; 5,7,8,3′,4′-pentamethoxyflavone; 5,7,8,4′-tetramethoxyflavone; 3,5,6,7,8,3′,4′-heptamethoxyflavone; 5-hydroxy-3,6,7,8,3′,4′-hexamethoxyflavone; 5-hydroxy-6,7,8,4′-tetramethoxyflavone; 5,6,7,4′-tetramethoxyflavone; 7-hydroxy-3,5,6,8,3′,4′-hexamethoxyflavone; or 7-hydroxy-3,5,6,3′,4′-pentamethoxyflavone. In certain embodiments, methods for preventing rebound... Agent: Jones Day

20070088079 - Prophylactic or therapeutic agent for sleep disorder: By combining one or more drugs selected from the group consisting of sedative antidepressants and antihistamines with (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, there is provided a prophylactic or therapeutic agent for sleep disorder that induces natural sleep, shortens sleep latency, increases deep sleep, is excellent in maintaining sleep, and exerts to attain appropriate sleep... Agent: Edwards & Angell, LLP

20070088080 - Gsk-3 inhibitors isolated from marine organisms: The present invention provides the use of a compound of formula (I); wherein: n is 0, 1, 2, or 3, the bonds shown with the dashed lines are saturated, or unsaturated with one or more double bonds; R, and R′are independently selected from hydrogen, alkyl, aryl, —OH, —OR″ —SH, —SR″—NH,... Agent: Fish & Richardson PC

20070088081 - Polyamine conjugates as selective nmda inhibitors and anti-cancer drugs: Polyamine compounds, method of synthesis and method of use for anti-cancer purposes, for enhancing the activity of existing anti-cancer drugs, as well as, for inhibiting N-Methyl-D-Aspartate (NMDA) receptors found in neurotransmission systems are provided. Certain polyamine motifs have been identified that can be attached to toxic agents to facilitate their... Agent: Law Offices Of Brian S Steinberger

20070088082 - Polymorphic forms of ladostigil tartrate: Provided are polymorphic forms of ladostigil tartrate and methods for preparation thereof.... Agent: Kenyon & Kenyon LLP

20070088083 - Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments: o

20070088084 - Malic acid addition salts of terbinafine:

20070088085 - Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands: The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen,... Agent: Bacon & Thomas, PLLC

20070088086 - Method of using synthetic l-se-methylselenocysteine as a nutriceutical and a method of its synthesis: A synthesis of and use for L-Se-methylselenocysteine as a nutriceutical is described, based upon the knowledge that L-Se-methylselenocysteine is less toxic than L-selenomethionine towards normal cells. The synthesis proceeds by mixing N-(tert-butoxycarbonyl)-L-serine with a dialkyl diazodicarboxylate and at least one of a trialkylphosphine, triarylphosphine, and phosphite to form a first... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070088087 - Concentrated x-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions: The present application is directed to the use of X-ray contrast media that act as universal antigens that are labeled herein as “pseudoantigens.” X-ray contrast media have the potential to exist in an aggregated state that is greater in increased concentrations. In this aggregated state, contrast media assume the role... Agent: Knobbe Martens Olson & Bear LLP

20070088088 - Method for preventing or treating metabolic syndrome: A method for preventing or treating metabolic syndrome by administering bezafibrate. Since bezafibrate suppresses the action of 11β-hydroxysteroid dehydrogenase type 1 and also accelerates expression of adiponectin receptor, it is used as an agent for preventing or treating metabolic syndrome.... Agent: Sughrue-265550

20070088089 - Methods for treating disorders associated with hyperlipidemia in a mammal: The invention is directed to methods for treating disorders associated with hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitapide) and a fibrate (for example, fenofibrate). Co-administration of the MTP inhibitor with the fibrate produces a therapeutic... Agent: Goodwin Procter LLP Patent Administrator

20070088090 - Alpha-bulnesene, its preparation and its use: e

20070082838 - Compositions and methods for preparation of poorly water soluble drugs with increased stability: The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions,... Agent: Morrison & Foerster LLP

20070082840 - Combination therapy for inhibition of platelet aggregation: The invention features methods for preventing platelet activation and aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. The methods are based on the intravenous, subcutaneous, or transdermal administration of a platelet activation or aggregation inhibitor, e.g., xemilofiban, followed by oral... Agent: Clark & Elbing LLP

20070082839 - Peptide increasing fusiogenic capacity of a gamete: The invention relates to a cyclic peptide increasing the fusiogenic capacity of the oocyte arising from the disintegrin loop of fertilin beta, to a pharmaceutical composition comprising said cyclic peptide and to the use thereof, particularly in order to supplement culture media used to carry out in vitro fertilization.... Agent: Nixon & Vanderhye, PC

20070082841 - Ocular administration of immunosuppressive agents: Methods and systems for preventing or treating various ocular conditions are disclosed and described. In one aspect, for example, a method for minimizing systemic exposure to a steroid-sparing immunosuppressive agent during treatment or prevention of an ocular condition is provided. Such a method may include administering a steroid-sparing immunosuppressive agent... Agent: Thorpe North & Western, LLP.

20070082845 - Ferritin as a therapeutic target in abnormal cells: Compositions for treatment of iron related diseases comprise an inhibitor of ferritin. An inhibitor of ferritin is active to reduce the level of H ferritin protein in a cell and/or to reduce the activity of H ferritin in a cell. Compositions providing cytoprotection, regulation of iron, increasing longevity and viability... Agent: Akerman Senterfitt

20070082843 - Implantable pump for protein delivery for obesity control by drug infusion into the brain: Methods and compositions are provided for suppressing appetite by surgically implanting a drug infusion pump into a site in a subject, and delivering a stable suspension of an appetite suppressing agent a region in a central nervous system of the subject. The appetite suppressing agent binds to a target receptor... Agent: Nutter Mcclennen & Fish LLP

20070082846 - Nucleotide and protein sequences of vertebrate delta genes and methods based thereon: The present invention relates to nucleotide sequences of vertebrate Delta genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the vertebrate Delta protein is a human protein. The invention further relates to fragments (and derivatives and analogs... Agent: Jones Day

20070082844 - Regulation of food preference using glp-1 agonists: GLP-1 agonists selectively decrease the amount of food intake, wherein the food has a high glycemic index or wherein the amount of mono-and di-saccharides together constitute a large proportion of the total amount of carbohydrates.... Agent: Novo Nordisk, Inc. Patent Department

20070082842 - Therapeutic applications for c-peptide: The present invention relates to administration of C-peptide in a once daily dose for use in the treatment of diabetes and diabetic complications.... Agent: Knobbe Martens Olson & Bear LLP

20070082847 - Variants of vascular endothelial cell growth factor, their uses, and processes for their production: The present invention involves the preparation of vascular endothelial growth factor (VEGF) variants which provide materials that are selective in respect of binding characteristics to the kinase domain region and the FMS-like tyrosine-kinase region, respectively KDR and FLT-1. The respective KDR and FLT-1 receptors are bound by corresponding domains within... Agent: Merchant & Gould PC

20070082848 - Vegf-c or vegf-d materials and methods for treatment of neuropathologies: The present invention relates to VEGF-C or VEGF-D materials and methods for promoting growth and differentiation of neural stem cells and materials and methods for administering said cells to inhibit neuropathology.... Agent: Marshall, Gerstein & Borun LLP

20070082849 - Angiogenic peptides and uses thereof: A peptide comprising an amino acid sequence as set forth in SEQ ID NO: 2, 4, 6, 8, 10 or 12 is provided. The peptide being at least 6 and no more than 50 amino acid residues in length. Also provided are therapeutic applications using such peptides.... Agent: Martin D. Moynihan Prtsi, Inc.

20070082850 - Mannose-6-phosphonate compounds for the treatment of inflammatory diseases: Novel phosphotetrahydropyran compounds that mimic mannose-6-phosphate but that are more resistant to phosphatases and mannosidases, and pharmaceutical compositions thereof, are disclosed. These compounds and compositions inhibit T lymphocyte migration from blood to tissues or to other extravascular sites. By inhibiting such migration, these compounds are useful for treating diseases or... Agent: Venable LLP

20070082851 - Treatment of a condition in a mammal with administration of compounds and methods of use: This invention relates to methods of treating, preventing, and lessening the severity of conditions or diseases selected from the group consisting of osteoarthritis (OA), rheumatoid arthritis, synovitis, subchondral bone edema, and cartilage degradation (“OA and related disorders”) with administration of an aminosugar derivative and pharmaceutically acceptable salts thereof.... Agent: Catalyst Law Group, Apc

20070082852 - Wound and skin care products: The invention provides compositions and methods that employ compounds that can stimulate proliferation of fibroblasts or keratinocytes and/or stimulate production of collagen by fibroblasts. These compositions and methods are useful for treating gum- and skin-related conditions.... Agent: Dority & Manning, P.A.

20070082853 - 6, 11-bridged tricyclic macrolides: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, PC

20070082854 - Novel polymorphs of erythromycin compound: The present invention relates to novel polymorphs of Telithromycin designated as Form I, II and III and its process for preparation. Also it provides Telithromycin with at least 99% purity.... Agent: Nixon & Vanderhye, PC

20070082856 - Combination therapy comprising the use of et-743 and doxorubicin for treating cancer: Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of doxorubicin is administered in combination with ET-743 in a dose range between 0.5 and 1 mg/m2. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with doxorubicin in... Agent: King & Spalding

20070082855 - Pharmaceutical formulations employing short-chain sphingolipids and their use: wherein: R1 is independently: an O-linked saccharide group; or an O-linked polyhydric alcohol group; or: R1 is independently: an O-linked (optionally N-(C1-4alkyl)-substituted amino)-C1-6alkyl-phosphate group; or an O-linked (polyhydric alcohol-substituted)-C1-6alkyl-phosphate group; R2 is independently C3-9alkyl, and is independently unsubstituted or substituted; R3 is independently C7-19alkyl, and is independently unsubstituted or substituted;... Agent: Nixon & Vanderhye, PC

20070082857 - Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac: Stable and clear aqueous solution preparations comprising an aminoglycoside antibiotic or a pharmacologically acceptable salt thereof and bromfenac being a nonsteroidal antiinflammatory agent or a pharmacologically acceptable salt thereof.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070082858 - Methods and compositions for the prevention of toxic side effects of aminoglycoside medications: Compositions and methods for reducing and/or preventing antibiotic-related damage to cells of the inner ear and the kidney are provided. Such compositions and methods reduce or prevent hearing loss and kidney damage resulting from use of antibiotics, such as aminoglycoside antibiotics. The composition also find use in reducing or preventing... Agent: Davis Wright Tremaine, LLP

20070082859 - Formulations of aica riboside: This invention relates to kits, compositions, and formulations comprising AICA riboside and analogs thereof and methods of using the same. The kits may comprise the compositions and/or formulations within a pH range, in a sterilized form. The kits may further comprise containers with a second therapeutic agent. The kits and... Agent: Wilson Sonsini Goodrich & Rosati

20070082865 - Compositions and methods for treatment of airway hypersecretion: The invention relates generally to the field of treating pulmonary diseases. More specifically, the invention relates to the treatment of airway hypersecretion by the administration of an inhibitor of the epidermal growth factor receptor (EGFR) signaling pathway in combination with an inhibitor of the interleukin-13 (IL-13) signaling pathway, as well... Agent: Senniger Powers

20070082861 - Ena nucleic acid drugs modifying splicing in mrna precursor: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070082860 - Hla-a24-restricted cancer antigen peptides: HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070082864 - Method for inducing a specific rnai activity in cells and nucleic acids for carrying out said method: A method for inducing activity of a specific RNAi into eukaryote cells in which the TAT protein and a nucleic acid coding for a nucleotide sequence comprising the sense and antisense sequences of an RNAi of interest are introduced, which sense and antisense sequences are separated by a separating nucleotide... Agent: Ip Group Of Dla Piper US LLP

20070082863 - Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds: A method of stimulating in vivo or ex vivo maturation of dendritic cells by applying an effective amount of inosine-containing compounds to the dendritic cells. The maturation of dendritic cells leads to more robust cellular immune responses against antigens including those associated with vaccines, infectious agents, and tumor cells by... Agent: Kohn & Associates PLLC

20070082862 - Novel antisense oligonucleotide and anti-hiv agent: A novel antisense oligonucleotide that targets at DIS (Dimerization Initiation Site) region of HIV-1; and an anti-HIV agent (HIV curative and/or preventive agent) comprising the same. This anti-HIV agent realizes effective treatment and/or prevention for HIV infection.... Agent: Heslin Rothenberg Farley & Mesiti PC

20070082866 - Novel immunogenic compositions for the prevention and treatment of meningococcal disease: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of... Agent: Hunton & Williams LLP Intellectual Property Department

20070082867 - Novel cyclodextrin dimers and derivatives thereof, methods for preparing them and their use, in particular, for the solubilizing pharmacologically active substances: The invention relates to a compound according to the following general formula (I), in which: m represents an integer equal to 5, 6 or 7; n and n1 represent an integer from 1 to 5; the A groups represent, in particular, a hydrogenated atom; X represents O or S; Y... Agent: Young & Thompson

20070082868 - Seaweed extract composition for treatment of diabetes and diabetic complications: A method and composition is described for prevention or treatment of Type II Diabetes Mellitus and its complications comprising the step of administering to a mammal an amount of seaweed extract in effective doses. The seaweed is selected from the group consisting of brown algae, red algae and green algae,... Agent: Inhouse Co.

20070082869 - Multistep process for the physical depolymerization of heparin and products obtained therefrom: The present invention is directed to a multistep process for the physical depolymerization of heparin wherein heparin is subjected to at least two γ-ray irradiations and wherein between two irradiation steps the depolymerised heparin is subjected to a separation step and only a fraction of the depolymerised heparin obtained from... Agent: Baker Botts, LLP

20070082870 - Pharmaceutical formulations of cyclodextrins and antifungal azole compounds: This invention relates to methods of increasing the aqueous solubility of an antifungal azole using hydroxybutenyl cyclodextrins. This invention also relates to method of increasing the bioavailability of an antifungal azole compounds administered to subjects.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070082871 - Antiresorptive mutual salt of raloxifene and bisphosphonic acid: The mutual salt of raloxifene and bisphosphonic acid exhibits unexpectedly synergistic effects of two components to enhance bone mineral density (BMD), control blood-calcium density, and lower the serum cholesterol level.... Agent: Sughrue Mion, PLLC

20070082873 - Combinations comprising ampa receptor antagonists for the treatment of schizophrenia: The present invention relates to combinations suitable for the treatment of psychiatric/neurological disorders, in particular schizophrenia. The combinations comprise at least one AMPA receptor antagonist and at least one compound selected from the group consisting of (a) anti-epileptic drugs selected from barbiturates and derivatives thereof, benzodiazepines, carboxamides, hydantoins, succinimides, valproic... Agent: Novartis Corporate Intellectual Property

20070082872 - Indole-containing compounds with anti-tubulin and vascular targeting activity: Trimethoxyphenyl substituted indole ligands have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin assembly. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070082874 - Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto: i

20070082875 - Compounds for preparing immunological adjuvant:

20070082876 - Novel c18 modified retrosteroids as progesterone receptor modulator compounds: Retrosteroidal compounds of formula I which act as progesterone receptor modulators, a method for their production, and pharmaceutical preparations containing these compounds. These compounds are preferably used for the treatment of benign gynecological disorders such as endometriosis and uterine fibroids, as well as for female birth control and for hormone... Agent: Crowell & Moring LLP Intellectual Property Group

20070082878 - Cytotoxic depsipeptides: Compounds of general formula (1) wherein R1, R2, R3 are as defined and R4 groups are each independently selected from NR2, O and S; are of use in treatment of cancers.... Agent: Fish & Richardson PC

20070082877 - Difluoromethylbenzanilides and use thereof for combating micro-organisms, intermediate products and use thereof: m

20070082879 - Imaging agents: The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210,... Agent: Greenlee Winner And Sullivan P C

20070082880 - Thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors: e

20070082881 - Compounds with modifying activity enhanced under hypoxic conditions: Compositions and methods for modifying one or more biologic targets are provided. Suitable targets include cells, DNA, proteins, enzymes, and/or a subject in need thereof. The compositions may exist as a monomer or multimer and are active in a biologic environment with enhanced activity in hypoxic environments and, thus, exhibit... Agent: Gardere Wynne Sewell LLP Intellectual Property Section

20070082882 - Transplatinum complexes with n2o2 donor sets as cytotoxic and antitumor agents: Trans-platinum compounds comprising carboxylato groups are disclosed, with anti-cancer usefulness. The carboxylato groups participate in solubilizing trans-platinum compounds to which they are attached.... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070082883 - Hiv protease inhibitors: Compounds useful for inhibiting HIV protease are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating wild-type HIV and of multidrug-resistant strains of HIV, also are disclosed.... Agent: Marshall, Gerstein & Borun LLP

20070082886 - Delta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it: m

20070082885 - Delta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it:

20070082884 - Selective serine/threonine kinase inhibitors: Inhibition of protein kinases having one or more cysteine residues within the ATP binding site is effected by contacting the kinase, per se or in a cell or subject, with an inhibitory-effective amount of a compound having a heterocyclic core structure comprised of two or more fused rings containing at... Agent: Townsend And Townsend And Crew, LLP

20070082887 - Amino methylated 2-pyridinones: Novel amino methylated 2-pyridinones, precursors, intermediates, and derivatives; the methods for the preparation of the same; uses of the same for inhibiting pili formation in bacteria; and pharmaceutical compositions comprising these compounds are described in this application. The present compounds may be employed to inhibit biofilm formation and thereby inhibit... Agent: Senniger Powers

20070082888 - Polyarylcarboxamides useful as lipid lowering agents: v

20070082889 - Pyridines useful as modulators of ion channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20070082890 - Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives: e

20070082891 - Novel pyrrolo[2,1-c] [1,4] benzodiazepine compounds and processes for the preparation thereof: The present invention provides novel pyrrolo [2,1-c][1,4]benzodiazepine compounds. This invention also provides a process for the preparation of novel pyrrolo[2,1-c][1,4]benzodiazepine compounds. These novel pyrrolo [2,1-c][1,4]benzodiazepine compounds are useful as antitumor agents. It also provides a process for the preparation of 7-methoxy-8-{n-[4-(2-oxo-2H-4-chromenyl)piperazino]alkyl}-oxy-(11aS)-1,2,3,11a-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one and 7-methoxy-8-{n-[4-(7-alkoxy-8-methyl-2-oxo-2H-4-chromenyl)piperazino]alkyl}-oxy-(11aS)-1,2,3,11a-5H-pyrrolo[2,1-c][1,4]. benzodiazepine-5-one with aliphatic chain length variations for... Agent: Knobbe Martens Olson & Bear LLP

20070082893 - Active substance combination: The present invention relates to an active substance combination comprising at least one substituted carbinol compound and at least one opioid, a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination and the use of said active substance combination for the manufacture of a medicament.... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070082892 - Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands: This invention relates to a compound of formula (I). The compound is useful for the treatment of gastrin related disorders.... Agent: Proskauer Rose LLP

20070082894 - Pyrazine-based tubulin inhibitors: A compound of general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating a hyperproliferation-related disease state or disorder in a subject using a compound of formula (I) is also described.... Agent: Morrison & Foerster LLP

20070082897 - Acylated indanyl amines and their use as pharmaceuticals: wherein R1—R4 have the meanings given in the description, A is CH2, CHOH or CH—(C1-C3-alkyl), B is CH2 or CH—(C1-C3-alkyl), and R5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description. These compounds are useful in the upregulation of endothelial nitric oxide synthase (eNOS),... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070082895 - Novel mycobacterial inhibitors: R3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; R4 is hydrogen, alkyl or benzyl; R5 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R5 radicals may be taken together to form together with the phenyl ring to which they are attached... Agent: Philip S. Johnson Johnson & Johnson

20070082896 - Tetrahydroquinoline derivatives and a process for preparing the same: wherein R1 is alkoxycarbonyl or the like, R2 is alkyl or the like; R3 is hydrogen or the like; R4 is alkylene or the like; R5 is optionally substituted heterocyclic group; R6, R7, R8 and R9 are independently hydrogen; alkyl, alkoxy, or the like; R10 is optionally substituted aromatic ring,... Agent: Birch Stewart Kolasch & Birch

20070082898 - 5 amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases: The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition mediated by a p38 MAP kinase; the compound being defined by formula (I): wherein: R1 and R2 are the same or different and each is... Agent: Heslin Rothenberg Farley & Mesiti PC

20070082899 - Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof: Compounds of Formulae (IA), (IB) or pharmaceutically acceptable salts thereof; wherein Het, X1, R1, R2, R3, R3a and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070082900 - Methods for inhibiting protein kinases: The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim kinases, and tyrosine kinase using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070082901 - Pyrazolopyrimidines as protein kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a] pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070082902 - Pyrazolopyrimidines as protein kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070082904 - Cycloalkyl derivatives of 3-hydroxy-4-pyridinones field of the invention: The present invention provides an cycloalkyl derivative of 3-hydroxy-4-pyridinone which is useful for the chelation of metal ions such as iron. Its preparation and use is described. In particular, the invention concerns the removal of iron in chemical and biological systems including chelating agents having the formula (I); wherein R1... Agent: Barrister & Solicitors

20070082903 - Remedy for rheumatoid arthritis: It is intended to provide a pharmaceutical composition for oral use which comprises SMP-114 or its pharmaceutically acceptable salt as the active ingredient, is designed so as to give an AUC0-24 level of at least about 2.7 μg·hr/mL and aims at reduction of chronic inflammation, reduction of structural damage, reduction... Agent: Sughrue Mion, PLLC

20070082905 - Pharmaceutical compositions comprising n-triazolymethyl-piperazine compounds and methods of using same: The present invention relates to N-triazolylmethyl-piperazine compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compositions in treating and preventing diseases and disorders.... Agent: Mayer, Brown, Rowe & Maw LLP

20070082906 - Inhibitors of akt activity: The present invention is directed to compounds which contain a heterocyclic triazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.... Agent: Merck And Co., Inc

20070082907 - Peroxisome proliferator activated receptor modulators: The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis,... Agent: Eli Lilly & Company

20070082909 - Acyclic ikur inhibitors: e

20070082908 - Bicycle pyrazole derivative: A compound represented by the following formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of either. These are compounds having high DPP-IV inhibitory activity and improved in safety, nontoxicity, etc. (I) [In the formula, R1 represents hydrogen, optionally substituted alkyl, etc.; the solid line and dotted line between... Agent: Sughrue Mion, PLLC

20070082910 - Specific nad(p)h oxidase inhibitor: The present invention provides an agent for inhibiting an excessive effect of NAD(P)H oxidase, which contains a compound that does not substantially inhibit the effect of leukocyte NADPH oxidase but inhibits the effect of NAD(P)H oxidase in tissues other than leukocytes, and a pharmaceutical composition containing said inhibitor.... Agent: Edwards & Angell, LLP

20070082911 - Novel use of quinolone antibiotics: The present invention relates to the use of certain quinolone antibiotics for controlling bacterial disorders of the oral cavity, in particular in veterinary medicine.... Agent: Jeffrey M. Greenman

20070082912 - Pyrrole compounds for the treatment of prostaglandine mediated diseases: e

20070082913 - Substituted heterocyclic compounds with cxcr3 antagonist activity: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070082914 - 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating pulmonary fibrosis:

20070082915 - Fungicidal mixtures for controlling rice pathogens:

20070082916 - Fungicidal mixtures for controlling rice pathogens: The invention relates to fungicidal mixtures for controlling rice pathogens, which comprise as the active components: 1) the triazolopyrimidine derivative of formula (I), and 2) a dithiocarbamate II selected from the group including manganese ethylenebis(dithiocarbamate) zinc complex (II.1), manganese ethylenebis(dithiocarbamate) (II.2), zinc ammoniate ethylenebis(dithiocarbamate) (II.3), zinc ethylenebis(dithiocarbamate) (II.4) and bis(dimethylthiocarbamoyl)disulfide... Agent: Birch Stewart Kolasch & Birch

20070082917 - Use of radical-scavenging compounds for treatment and prevention of no-dependent microcirculation disorders: A method of treatment of the human or non-human animal body for treating NO-dependent microcirculation disorders is disclosed, for example microcirculation disorders caused by metabolic diseases, such as elevated levels of homocystin-homocystein inflammatory reactions or autoimmune diseases, furthermore peripheral microcirculation disorders or microcirculation disorders associated with increased cell fragmentation, which... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070082918 - Neurologically active compounds and compounds with multiple activities: Pharmacologically active compounds suitable for treating a mammal so as to affect neurological function, the compounds comprising at least two neurologically active groups, one group providing alpha-adrenergic agonist activity, and the second group providing agonist activity selected from the group consisting of beta-adrenergic agonist activity, serotinergic agonist activity, dopaminergic agonist... Agent: Paul J. Sutton, Esq., Barry G. Magidoff, Esq. Greenberg Traurig, LLP

20070082919 - Process for preparing a co-precipitate of a non-crystalline solid drug substance: The present invention provides processes for preparing co-precipitates of non-crystalline, solid drug substances, such as (E)-4-(1,3-bis(cyclohexylmethyl)-1,2,3,6 -tetrahydro-2,6-dioxo-9H-purin-8-yl)cinnamic acid nonaethylene glycol methyl ether ester and solvates thereof.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070082920 - Nad+-dependent dna ligase inhibitors: wherein R5 and R6 are independently unsubstituted or substituted, wherein each substituent is independently selected from halogen, amino, alkyl (C1-C6), haloalkyl (C1-C6), alkoxy(C1-C6), alkylenedioxy, aryl, heteroaryl, and cycloalkyl (C3-C8). Also disclosed are methods for the preparation of compounds of Formula I and various intermediates. These compounds are useful as NAD+-dependent... Agent: Fay Sharpe LLP

20070082921 - Quinazoline derivatives as antitumor agents: The invention concerns quinazoline derivatives of Formula (I); wherein each of Q<1>, Q<2>, Z, R<1>, R<2>, R<3>, and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention... Agent: Morgan Lewis & Bockius LLP

20070082922 - Huperzine a prodrugs and uses thereof: Disclosed are huperzine A prodrugs and method of synthesis thereof. The invention further relates to methods of treating, preventing or reversing neurodegenerative diseases, such as, Alzheimer's Disease and neuronal dysfunctions, such as, memory impairment using a pharmaceutical composition comprising a huperzine A prodrug as disclosed herein.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070082923 - Process for the synthesis of compounds for selectin inhibition: s

20070082924 - Processes for preparing different forms of (s)-(+)- clopidogrel bisulfate: The invention provides improved processes for the preparation of hydrated form of (S)-(+)-Clopidogrel bisulfate as well as improved processes for the preparation of form-I and form-II of (S)-(+)-Clopidogrel bisulfate.... Agent: Nixon & Vanderhye, PC

20070082925 - Method for the preparation of montelukast acid and sodium salt thereof in amorphous form: A method for the preparation of montelukast acid sodium salt thereof in amorphous form has been described. The method comprises of following steps: (a) generating the dilithium dianion of 1-(mercaptomethyl)cyclopropane acetic acid, by reacting with alkyl lithium, (b) coupling the said dianion with wet mesylate to get montelukast acid in... Agent: Louis M Heidelberger Reed Smith

20070082926 - Novel polymorphs of racemic, dextrorotatory, and levorotatory enationers of 1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo- quinoline-3-carboxylic acid hydrochloride and mesylate salts: A polymorphic forms of the hydrochloride salt and mesylate salt of racemic (±)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid, dextrorotatory R-(±)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid and S-(−)-1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3,3-dimethylpiperidin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid having formula (I) and (II) respectively are described. Processes for their preparation are also described. The invention further relates to methods of using, and pharmaceutical compositions comprising the compounds of... Agent: Bio Intellectual Property Services (bio Ips) LLC

20070082927 - Piperidine derivative having nmda receptor antagonistic activity: p

20070082928 - Method for treating anxiety disorders, substance abuse/dependence, binge-eating disorders, insomnia and drug-induced flashbacks: A method for treating anxiety disorders and other disorders using cholinesterase inhibitors including donepezil and its pharmaceutically acceptable salts.... Agent: Vidas, Arrett & Steinkraus, P.A.

20070082929 - Inhibitors of the gastric h+, k+-atpase with enhanced therapeutic properties: Chemical syntheses and medical uses of novel inhibitors of the gastric H+, K+-ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.... Agent: Knobbe Martens Olson & Bear LLP

20070082930 - Pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti-inflammatory drug: The invention provides a pharmaceutical composition, pharmaceutical product or kit comprising a first active ingredient which is a P2X7 receptor antagonist, and a second active ingredient which is a nonsteroidal anti-inflammatory drug, for use in the treatment of inflammatory disorders.... Agent: Fish & Richardson P.C.

20070082931 - Indole derivatives: e

20070082932 - Pyrrolidine compounds:

20070082933 - Novel thiazolidin-4-one derivatives: The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.... Agent: Dickstein Shapiro LLP

20070082934 - Substituted 4-aryloxy and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of cell proliferation: The invention discloses compounds which are substituted 4-aryloxy and 4-arylsulfanyl-phenyl-2-aminothiazoles with anti-cancer activity. The invention futher discloses methods of preparing compounds of the invention. The invention also discloses methods of inhibiting cell proliferation and tumor growth in a subject by administering compounds of the invention to the subject.... Agent: University Of Virginia Patent Foundation

20070082935 - Method for disinfecting or sanitizing a surface: A method for disinfecting or sanitizing a surface by applying an antimicrobial composition comprising a metal-polymer complex.... Agent: Rohm And Haas Company Patent Department

20070082936 - Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives: R1, R2, R3, R4, and R5 are as defined in the specification and claims and with their pharmaceutically acceptable acid addition salts. The invention also relates to methods for preparing such compounds. This class of compounds has a high affinity and selectivity for GABA A α5 receptor binding sites and... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070082937 - Anti cancer combinations comprising a cox-2 inhibitor: The present invention relates to synergistic combinations of the compounds of formula (I) such as compounds of the xanthenone acetic acid class such as 5,6dimethylxanthenone-4-acetic acid (DMXAA) and a selective COX-2 inhibitor, in particular rofecoxib, which have anti-tumour activity. More particularly, the invention is concerned with the use of such... Agent: Nixon & Vanderhye, PC

20070082939 - Methods and compositions for the treatment of neuropathies and related disorders: The present invention provides novel compositions and methods for treating symptoms associated with neuropathic disorders such as hyperalgesia, allodynia, and parasthesias, using a 1-aryl-3-azabicyclo[3.1.0] hexane. The invention further relates to the use of 1-aryl-3-azabicyclo[3.1.0] hexanes in pharmaceutical compositions and methods for treating neuropathic disorders and related symptoms in mammals. Patients... Agent: Black Lowe & Graham PLLC

20070082940 - Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.... Agent: Black Lowe & Graham PLLC Suite 4800

20070082938 - Polymorphs of bicifadine hydrochloride: A new polymorphic crystalline form of bicifadine hydrochloride, designated form B, which is more thermodynamically stable than the previously known polymorphic form of bicifadine hydrochloride, designated as form A, methods for preparing said crystalline form B and pharmaceutical compositions containing said crystalline form B.... Agent: Black Lowe & Graham PLLC Jeffrey J. King, Esq.

20070082941 - Crystalline sulfonamide-containing indole compound and process for preparing the same: A crystalline form of N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide having a diffraction peak at a diffraction angle (2θ±0.2°) of 19.1° in a powder X-ray diffraction.... Agent: Birch Stewart Kolasch & Birch

20070082942 - Prevention of hiv-1 infection by inhibition of rho-mediated reorganization and/or content alteration of cell membrane raft: The present invention relates generally to the prevention or delaying of retroviral infection by use of agents that prevent the clustering of retroviral receptors associated with cell membrane raft domains. The present invention relates more specifically to the prevention or treatment of HIV-1 infection through the use of agents that... Agent: Connolly Bove Lodge & Hutz LLP

20070082943 - Process for preparation of substantially pure glimepiride: The present invention discloses a novel process for purification of trans-4-methyl cyclohexylamine HCl and 4[-2-(3-Ethyl-4-methyl-2-carbonyl pyrrolidine amido) ethyl] benzene sulfonamide used in the synthesis of 3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(trans-4-methyl cyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide (I), popularly known as Glimepiride. The present invention also discloses a novel purification of Glimepiride usingS methanolic ammonia and glacial acetic acid to... Agent: Pharmaceutical Patent Attorneys, LLC

20070082944 - Antimicrobial compositions and methods of use: A catechin is modified in at least one position (most preferably in the 3-position of the C-ring) to increase its lipophilicity. Contemplated catechins are demonstrated to have significantly improved antibacterial properties, likely due to catastrophic membrane damage.... Agent: Hani Z. Sayed, Esq. C/o Rutan & Tucker, LLP

20070082945 - Discodermolide compositions: Pharmaceutical formulations comprising discodermolide in the form of an infusion concentrate, and methods of administration of discodermolide in suitable form for parenteral administration.... Agent: Novartis Corporate Intellectual Property

20070082946 - Methods of treating mental diseases, inflammation and pain: a

20070082947 - Use of phthalide derivatives for the treatment and prevention of diabetes mellitus: The present invention relates to the use of a compound as effective agent for the prevention or treatment of diabetes mellitus in a mammal. Said compounds being selected from the group of phthalide derivatives and exhibit excellent blood glucose lowering effects and thus are effective agents in the prevention or... Agent: Stephen M Haracz Bryan Cave

20070082948 - Compounds and methods for delivery of prostacyclin analogs: This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and... Agent: Foley And Lardner LLP Suite 500

20070082949 - Agent for preventing and treating language disorders: A highly effective, safe agent for preventing and treating language disorders containing at least one member selected from the group consisting of icosapentaenoic acid and its salt and ester as an effective component is provided. The agent exhibits remarkable therapeutic effects for language disorder with no adverse side effects.... Agent: Birch Stewart Kolasch & Birch

20070082950 - Method for producing vitamin a acetate: The present invention relates to a process for preparing vitamin A acetate by reacting β-vinylionol with triphenylphosphine in the presence of sulfuric acid in a solvent mixture consisting of 60 to 80% by weight methanol, 10 to 20% by weight water and 10 to 20% by weight aliphatic, cyclic or... Agent: Connolly Bove Lodge & Hutz, LLP

20070082951 - Abiotic heparin antagonists: The present invention relates to heparin-binding calixarene compounds of general Formula (I) in which R, R1, L and n have the meanings indicated in the description and their use in the biomedical field.... Agent: Young & Thompson

20070082952 - Pharmaceutical compositions, methods of preparation thereof, and methods of treatment: The present invention provides compositions, useful as pharmaceuticals, comprising 3-biphenyl-4-yl-(2S)-[(4′-trifluoromethyl-biphenyl-4-carbonyl)-amino]-propionic acid. Also disclosed are methods for preparing the compositions and methods for using the compositions.... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20070082953 - Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases: The present invention concerns the use of L-dopa, its derivatives or physiologically compatible salts thereof for the prophylaxis of psychotic disorders and for the treatment of diseases which are caused by disrupted tyrosine transport or disrupted tyrosine decarboxylase. In addition, the invention concerns pharmaceutical compositions which contain L-dopa, its derivatives... Agent: Kriegsman & Kriegsman

20070082954 - Pharmaceutical compositions containing (+) cannabidioil and derivatives thereof and some such novel derivatives: Cannabinoid derivatives are known for their functions in the central as well as peripheral nervous system. The present invention describes some novel (+)-cannabidiol (CBD) derivatives, and their selective activity in the peripheral and not in the central nervous system. Thus, it is an object of the invention to provide the... Agent: Kevin D Mccarthy Roach Brown Mccarthy & Gruber

20070082955 - Novel target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto: The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound that specifically binds to KSRP or a functional fragment thereof, and a screening method for the compound. KSRP is a novel target protein for anticancer agents; a compound capable of regulating the expression and activity of... Agent: Barnes & Thornburg LLP

20070082956 - The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity.: The invention relates to a novel use of 1-amino-alkylcyclohexane NMDA receptor antagonists such as neramexane in the treatment of pain hypersensitivity and neuropathic pain.... Agent: The Firm Of Hueschen And Sage

20070082957 - Adamantane derivatives: The invention provides adamantane derivatives of formula (I), a process for the their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula... Agent: Morgan Lewis & Bockius LLP

20070082958 - Methods for treatment of renal failure: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of renal failure.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070078077 - Enhanced ocular neuroprotection and neurostimulation: Use of topically applied cyclosporine to enhance corneal sensitivity restoration rate in an eye of an individual after ocular surgery such as laser-assisted in situ keratomileusis (LASIK) in which nerves are severed.... Agent: Wood, Herron & Evans, LLP

20070078076 - Intracorporeal medicaments for high energy phototherapeutic treatment of disease: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of... Agent: Cook, Alex, Mcfarron, Manzo, Cummings & Mehler Ltd

20070078078 - Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues: Disclosed herein are guanidinium containing compounds consisting of a core moiety with a plurality of side chains containing guanidinium groups. Such compounds have enhanced translocation across cellular membranes and epithelial tissues. The compounds may also have a therapeutic or other biologically active moiety attached so that these moieties may be... Agent: Knobbe Martens Olson & Bear LLP

20070078081 - Antiviral compounds: The invention is related to HCV inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compound.... Agent: Intellectual Property Department Gilead Sciences, Inc.

20070078080 - N4-acylcytosine nucleosides for treatment of viral infections: The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2′,3′-dideoxy-5-fluorocytidine or N.sup.4-acyl-2′,3′-didehyd-ro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives... Agent: Merchant & Gould PC

20070078079 - Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity: Template-fixed β-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12, 14 or 18 α-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid), are Gly, NMeGly, Pro or Pip, or of certain types which, as the... Agent: Hoffmann & Baron, LLP

20070078082 - Methods and compositions to treat glycosaminoglycan-associated molecular interactions: Therapeutic compounds and methods for inhibiting a glycosaminoglycan (GAG)-associated molecular interaction in a subject, whatever its clinical setting, are described... Agent: Lahive & Cockfield, LLP

20070078083 - Modulation of neuorgenesis by hdac inhibition: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on an HDac inhibitory agent alone or in combination with another neurogenic agent to stimulate or activate the formation of new... Agent: Townsend And Townsend And Crew, LLP

20070078084 - Compositions and methods related to production of erythropoietin: Disclosed are methods and compositions that are related to the production of erythropoietin. The disclosed compositions generally comprise a poly amino acid, such as a poly amino acid comprising one or more glutamic acid residues. The production of erythropoietin by use of the disclosed compositions and methods can take place... Agent: Needle & Rosenberg, P.C.

20070078089 - Method for effecting changes in the central nervous system by administration of igf-i or igf-ii: The invention concerns a method for effecting changes in the central nervous system, including treatment of brain and spinal cord disorders or diseases, by parenteral administration of insulin-like growth factors I (IGF-I) or insulin-like growth factor II (IGF-II).... Agent: Howrey LLP

20070078085 - Methods and compositions for the utilization and targeting of osteomimicry: The present invention relates to compositions and methods for modulating osteomimicry within tumor and tissue cells with calcification potential. The invention further relates to screening compounds that modulate osteomimicry within tumor and tissue cells with calcification potential. Methods for using compounds identified by the screening assays for therapeutic treatments also... Agent: Patent Administrator Katten Muchin Rosenman LLP

20070078088 - Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 952: The present invention relates to methods for the diagnosis and treatment of a cancer or cancer. Specifically, the present invention identifies the differential expression of 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427,... Agent: Millennium Pharmaceuticals, Inc.

20070078087 - Use of factor viia or factor viia equivalents for treating trauma: The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for treatment of trauma.... Agent: Novo Nordisk, Inc. Patent Department

20070078086 - Uses of factor viia or factor viia equivalents for treating late complications of trauma: The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for preventing late complications in trauma patients.... Agent: Novo Nordisk, Inc. Patent Department

20070078090 - Anti-chrondrosarcoma compounds: The invention provides inhibitors of chondrosarcoma cell growth that are useful as anti-cancer and anti-tumor agents. The inhibitors are peptides having sequences related to cleavage regions of the proenzyme forms of matrix metalloproteinases and that can inhibit the activity of matrix metalloproteinases. The peptide inhibitors of the invention can be... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070078091 - Pharmaceutical combinations for compensating for a testosterone deficiency in men while simultaneously protecting the prostate: This invention relates to pharmaceutical combinations for compensating for an absolute and relative testosterone deficiency in men with simultaneous prophylaxis for the development of a benign prostatic hyperplasia (BPH) or prostate cancer. The combinations according to the invention contain a natural or synthetic androgen in combination with a gestagen, an... Agent: Millen, White, Zelano & Branigan, P.C.

20070078092 - Cell permeable conjugates of peptides for inhibition of protein kinases: The present invention provides inhibitors of protein kinases comprising a molecule having at least a first moiety competent for penetration of the molecule into cells, and a second moiety for having a protein kinase inhibiting effect within the cells. The first moiety is joined to the second moiety through a... Agent: Winston & Strawn LLP Patent Department

20070078095 - Compounds and methods for delivery of prostacyclin analogs: This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and... Agent: Foley And Lardner LLP Suite 500

20070078094 - Guanidinium delivery carriers: Disclosed herein are transmembrane transporter compounds containing guanidinium groups. Also disclosed herein are methods for transporting a biologically active moiety across a biological membrane using the transmembrane transporter compounds. Particularly, this invention provides a method for the delivery of a biologically active moiety across the biological membranes of such membranes... Agent: Knobbe Martens Olson & Bear LLP

20070078093 - Methods and compositions for treating cancer: Pharmaceutical compositions and kits useful for the treatment of cancer include certain alkyl esters of cystine and certain alkyl-substituted cystamine derived esters, including, for example, cystine dimethyl ester and a di-alkyl peptidyl cystamine ester, among others. These compounds may be employed in methods of treating cancers or methods of determining... Agent: Howson And Howson

20070078096 - Buffered drug formulations for transdermal electrotransport delivery: Buffered drug formulations for transdermal electrotransport delivery are disclosed. The formulations utilize a dipeptide as a buffer and allow for more efficient electrotransport delivery of drugs, e.g., polypeptide drugs, via the transdermal route.... Agent: Philip S. Johnson Johnson & Johnson

20070078098 - Anti-hypercholesterolemic compounds: f

20070078097 - Method for treating intermittent claudication comprising the administration of propionyl l-carnitine and a concomitant physical training: The present invention discloses a method for treating a subject suffering from intermittent claudication (IC) wherein said subject takes an effective dose of propionyl L-carnitine or a pharmaceutically acceptable salt thereof and also engaging in a concomitant physical training program. The method is particular effective for patients with intermittent claudication... Agent: Nixon & Vanderhye, PC

20070078099 - Method of preventing, treating and diagnosing disorders of protein aggregation: Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof.... Agent: Millen, White, Zelano & Branigan, P.C.

20070078100 - Methods of detecting poly(adp-ribose) polymerase and other nad+ utilizing enzymes: Methods for detecting poly (ADP-ribose) polymerase and other NAD+ utilizing enzymes.... Agent: Evan Law Group LLC

20070078103 - Formulations comprising antisense nucleotides to connexins: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation... Agent: Duane Morris LLP

20070078104 - Immunostimulatory nucleic acid molecules: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.... Agent: Wolf Greenfield & Sacks, PC

20070078105 - Methods and means for obtaining modified phenotypes: Methods and means are provided for reducing the phenotypic expression of a nucleic acid of interest in eucaryotic cells, particularly in plant cells, by introducing chimeric genes encoding sense and antisense RNA molecules directed towards the target nucleic acid, which are capable of forming a double stranded RNA region by... Agent: Buchanan, Ingersoll & Rooney PC

20070078102 - Nf-kb oligonucleotide decoy molecules: The present invention concerns double-stranded NF-κB decoy oligodeoxynucleotide (NF-κB dsODN) molecules that contain a core sequence capable of specific binding to an NF-κB transcription factor. In a particular aspect, the invention concerns NF-κB decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers. In another aspect, the invention... Agent: Heller Ehrman LLP

20070078101 - Regulation of tgf-beta signaling by tomoregulin: The present invention provides methods of modulating TBF-β, particularly, nodal, Vg1 or BMP-2, but not activin, signalling by administration of a molecule that modulates the activity of TMEFF1. Diagnostic methods are also provided.... Agent: King & Spalding

20070078106 - Uracil reductase inactivators: Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-flourouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, ido, cyano, halo-substituted C1-4 alkyl C2-6 alkenyl, 1-halo-C2-6 alkenyl and halo-substituted C2-6 alkynyl.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070078107 - Use of lipid conjugates in the treatment of disease: This invention provides a method of preventing or treating a dermatologic condition including, inter alia, psoriasis, contact dermatitis, and atopic dermatitis, in a subject, the method includes the step of administering to said subject a compound comprising a lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer,... Agent: Pearl Cohen Zedek Latzer, LLP

20070078109 - Compositions and methods used to treat acne and candida: Disclosed herein is a water-soluble chelated complex of a co-polymer of N-acetylglucosamine-glucosamine pyrithione sale (AGP). This composition is characterized by a highly viscose texture with excellent surface properties and extremely long acting antimicrobial activity. AGP's antimicrobial activity against acne bacteria has been found superior to the benzyl peroxide the leading... Agent: Greenberg Traurig, LLP

20070078108 - Liquid composition for bulging mucous membrane for use in endoscopic surgery comprising a chitosan derivative containing carbohydrate chains: The present invention provides a liquid composition to make the mucous membrane bulge during endoscopic surgery characterized in that it comprises a chitosan derivative containing carbohydrate chains. The use of the composition of the present invention as a liquid for bulging the mucous membrane during endoscopic surgery, maintain the bulge... Agent: Pearne & Gordon LLP

20070078110 - Emulsifications-stable pesticidal composition: An object of the present invention is to provide an emulsification-stable pesticidal composition having ant-control, rotcontrol and mildew-control effects. Another object of the present invention is to provide a composition having pesticidal effects, and particularly antimicrobial effects, for protecting industrial materials such as wood, pulp, paper, fibers, adhesives, films subject... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20070078111 - Lpa2 receptor agonist inhibitors of cftr: Methods and compositions for treating or preventing diarrhea are disclosed. The methods comprise administering to an individual a therapeutically effective amount of an LPA2 receptor agonist for treating or preventing diarrhea. Also disclosed is a method of inhibiting CFTR activation by administering at least one LPA2 receptor agonist in an... Agent: Donna J. Russell

20070078112 - Phosphate prodrugs of a farnesyl dibenzodiazepinone, processes for their production and their use as pharmaceuticals: This invention relates to phosphate prodrugs of a farnesylated dibenzodiazepinone, to processes of their manufacture, to pharmaceutical compositions comprising the prodrugs, and to their use in the treatment of neoplasms.... Agent: Sughrue Mion, PLLC

20070078113 - Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for... Agent: Fulbright & Jaworski L.L.P.

20070078114 - Combination therapy for alzheimer's disease and other diseases: The invention relates to combinations of one or more Aβ42 lowering agents and one or more hormonal modulating agents.... Agent: Myriad Genetics Inc. Intellecutal Property Department

20070078115 - Phytosterol and/or phytostanol derivatives: The present invention relates to a phytosterol and/or a phytostanol ester compound produced from the reaction of a phytosterol and/or a phytostanol with a polyunsaturated fatty acid (PUFA), wherein the polyunsaturated fatty acid has from 18 to 22 carbon atoms and at least three carbon-carbon double bonds. Processes for producing... Agent: Stephen M. Haracz, Esq. Bryan Cave LLP

20070078116 - Method of treatment of otitis externa: This invention relates to a method of treating otitis externa, and in particular otitis externa of fungal etiology, using topical medication, including antifungal agents such as itraconazole and miconazole, and optionally also including a second antifungal agent, which is formulated for topical application to the external ear canal, preferably as... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070078117 - Methods for the treatment of a traumatic central nervous system injury: Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of... Agent: Alston & Bird LLP

20070078118 - Microbicidal composition: Synergistic microbicidal compositions containing N-(n-butyl)-1,2-benzisothiazolin-3-one or N-methyl-1,2-benzisothiazolin-3-one.... Agent: Rohm And Haas Company Patent Department

20070078119 - Storage system for texaphyrin pharmaceutical formulations: A packaging system is described for a drug that provides protection from contamination, crystallization and/or degradation of the drug during storage of the system prior to its use. The packaging of the drug does not significantly absorb, react with, or otherwise adversely affect the therapeutic effectiveness of the drug or... Agent: Wilson Sonsini Goodrich & Rosati

20070078120 - Novel piperidine derivative: p

20070078121 - Enzyme modulators and treatments: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, immunological disorders, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of kinases, including p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein,... Agent: Hovey Williams LLP

20070078122 - Indolobenzazepine hcv ns5b inhibitors: The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070078124 - 1-aza-2-oxa-dibenzo(e,h)azulenes and their use for the treatment of central nervous system diseases and disorders: The present invention relates to 1-aza-2-oxa-dibenzo[e,h]azulenes, their pharmacologically acceptable salts and solvates, processes and intermediates for the preparation thereof and to the use thereof in pharmaceutical formulations for the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochemical equilibrium... Agent: Darby & Darby P.C.

20070078123 - 1-thia-3-aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders: The present invention relates to the use of derivatives from the group of 1-thia-3-aza-dibenzo[e,h]azulenes and of their pharmaceutically acceptable salts and solvates in a pharmaceutical formulation for the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochemical equilibrium of... Agent: Darby & Darby P.C.

20070078125 - Arylamine mch r1 antagonists: This invention relates to novel arylamines which are antagonists of the melanin-concentrating hormone receptor 1 (MCH R1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in medicines for the treatment of obesity, diabetes, depression, and/or anxiety. Compounds of the invention have the formula:... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070078126 - Compounds, compositions and methods: Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070078127 - Control of arthropods in animals: A method of controlling parasites in or on an animal comprising administering to the animal a parasiticidally effective, substantially non-emetic 1-arylpyrazole.... Agent: Buchanan, Ingersoll & Rooney PC

20070078128 - Non-nucleoside reverse transcriptase inhibitors: The present invention provides compounds of formula I where R1 to R4 are as defined herein which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides for methods of treating or preventing HIV infection with compounds according to... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070078129 - Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes: e

20070078130 - Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases: The present invention relates to substances capable of specifically inhibiting Ala-p-nitroanilide-cleaving peptidases and Gly-Pro-p-nitroanilide-cleaving peptidases as well, for a use in the medical field. Furthermore, the invention relates to the use of at least one of such substances or of at least one pharmaceutical or cosmetic composition containing at least... Agent: Greenblum & Bernstein, P.L.C

20070078131 - Thieno-pyridinone derivatives as kinase inhibitors: A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 3-position by an arylcarbonyl or heteroaryl-carbonyl moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.... Agent: Woodcock Washburn LLP

20070078132 - Pyrido-and pyrimidopyrimidine derivatives as anti-profilerative agents: s

20070078133 - Cyclobutyl amine derivatives:

20070078134 - Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto:

20070078135 - Substituted heteroaryl cb1 antagonists: In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders.... Agent: Edwards & Angell, LLP

20070078136 - Fused heterocyclic compounds useful as kinase modulators:

20070078137 - Method of inhibiting neurotrophin-receptor binding: The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTR comprises, particularly when bound to nerve growth factor, at least two... Agent: Gowling Lafleur Henderson LLP

20070078138 - Analogs of dehydrophenylahistins and their therapeutic use: e

20070078140 - Met kinase inhibitors:

20070078141 - Piperazine amidines as antiviral agents: This disclosure provides compounds of Formula I as described herein having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with indole and azaindole piperazine diamide derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for... Agent: Louis J. Wille Bristol-myers Squibb Company

20070078139 - Phosphodiesterase 4 inhibitors: i

20070078142 - Treatment of tuberous sclerosis associated neoplasms: in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of tuberous sclerosis associated neoplasms; to a method of treatment of warm-blooded animals, including humans, suffering from a tuberous... Agent: Novartis Corporate Intellectual Property

20070078143 - Method for preparing ziprasidone monohydrochloride-hydrate: Ziprasidone is a known agent for treating various disorders including schizophrenia, migraine pain and anxiety. The present invention provides a method for preparing 5-(2-(4-1,2-benzisothiazol-3-yl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one (Ziprasidone) monohydrochloride-hydrate or a pharmaceutically acceptable acid addition salt thereof.... Agent: Iplm Group, P.A.

20070078144 - Agents for treating neurodegenerative diseases: The present invention relates to compounds effective in preventing neuronal cell death, which may be used in the treatment of neurodegenerative diseases. It is based, at least in part, on the discovery that particular compounds were effective in preventing neuronal death in model systems of Huntington's Disease.... Agent: Baker & Botts L.L.P.

20070078145 - Inhibitors of ion channels: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides heterocyclic aryl sulfonamides, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly... Agent: Morgan, Lewis & Bockius LLP (sf)

20070078146 - Substituted pyrazoles as p38 kinase inhibitors: m

20070078147 - Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which... Agent: Millen, White, Zelano & Branigan, P.C.

20070078148 - Agents for preventing and/or treating higher brain dysfunctions: e

20070078149 - 6-(2-halophenyl)triazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds: L3 is hydrogen, halogen, cyano, nitro, haloalkyl, alkoxy or alkoxycarbonyl; X is halogen, cyano, alkyl, haloalkyl, alkoxy or haloalkoxy; processes and intermediates for preparing these compounds, compositions comprising them and their use for controlling phytopathogenic harmful fungi.... Agent: Birch Stewart Kolasch & Birch

20070078150 - Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto:

20070078151 - Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds: Crystals of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one having a diffraction peak at a diffraction angle (2θ±0.2°) of 9.7° and/or 21.9° in a powder X-ray diffraction are suitable for an active ingredient of a preventing and therapeutic agent for diseases such as constipation. Crystals of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one hydrate and amorphous 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one hydrate are also suitable for... Agent: Birch Stewart Kolasch & Birch

20070078153 - 4-oxoimidazolidine-2-spiropiperidine derivatives: [in which A1, A2, A3, A4 and A5 stand for optionally halogen-substituted methine, or nitrogen atom; R1 and R2 stand for lower alkyl or the like; R3 stands for hydrogen or lower alkyl; R4 and R5 stand for hydrogen, or lower alkyl which is optionally substituted with hydroxy, or the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070078152 - Piperidine derivatives: Compounds, compositions and methods are provided that are useful in the treatment or prevention of conditions or disorders associated with a neuropeptide receptor. The subject methods are particularly useful in the treatment and/or prevention of endocrine, metabolic, cardiovascular, neurologic, psychiatric, gastrointestinal, genitourinary and other disorders.... Agent: Jones Day

20070078154 - Quinoline potassium channel inhibitors: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20070078155 - Naphthyridin derivatives: e

20070078156 - Derivatives of n-(1h-indazolyl)-and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for treatment of pain: Compounds of formula (I): wherein A, B and D are each C, N, O or S; E is C or N; the dotted circle within the five-membered ring indicates that the ring may be unsaturated or partially saturated; R1 is halogen, hydroxy, C1-6 alkyl, haloC1-6 alkyl, hydroxyC1-6 alkyl, C1-6 alkoxy,... Agent: Merck And Co., Inc

20070078157 - Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (ssao)enzyme activity and vap-1 mediated adhesion useful for treatment of diseases: Compositions and methods are disclosed for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). The compounds disclosed are amine-containing and amide-containing compounds. The compounds and compositions are useful for treatment of diseases, including inflammation, inflammatory diseases and autoimmune disorders.... Agent: Morrison & Foerster LLP

20070078158 - Purification of montelukast: The present invention provides methods of purifying montelukast, a new isolated impurity of montelukast, method for its isolation, and method of using montelukast impurity as a reference marker and a reference standard.... Agent: Kenyon & Kenyon LLP

20070078159 - A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amin ophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same: A crystal of a 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide hydrochloride, hydrobromide, p-toluenesulfonate, sulfate, methanesulfonate or ethanesulfonate, or a solvate thereof.... Agent: Birch Stewart Kolasch & Birch

20070078160 - Dihydro-[1h]-quinolin-2-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes: c

20070078161 - Crystalline forms of (+)- and (-) erythro-mefloquine hydrochloride: (+)- or (−)-erythro-Mefloquine hydrochloride can exist in four crystalline forms A, B, C and D, whereby form A is the most stable form. Form A can be directly produced in morphological forms like thick columns, cuboids, cubes and cube-like forms, which can be easily handled during processing and formulation. (+)-... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070078162 - Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists: The present invention relates to the use of compounds and compositions of compounds having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena-etc). The invention also relates to methods comprising administering... Agent: Amster, Rothstein & Ebenstein LLP

20070078163 - Substituted pyrrolidine and related compounds: e

20070078164 - 4-phenylpiperidine derivatives as renin inhibitors: exhibit inhibitory activity on the natural enzyme renin. Thus, compounds of formula (I) may be employed for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as... Agent: Novartis Corporate Intellectual Property

20070078165 - Mch receptor antagonists: h

20070078166 - Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3] triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone: The present invention provides novel crystalline forms of {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone, compositions thereof, intermediates thereof, methods of using the same, processes for making the same, and processes for making intermediates thereof.... Agent: Eli Lilly & Company

20070078167 - Use of bipyridine compound 'caerulomycin a' derivatives and analogs thereof as immunosuppressive agents: The present invention relates to an isolated bioactive molecule Caerulomycin A, derivatives and analogs thereof as effective immunosuppressive agents. The immunosuppressive property of the compound is targeted in particular against the lymphocytes, CD4+ T cells, CD8+ T cells and B cells and in the production of IL-4 and IFN-γ and... Agent: Birch Stewart Kolasch & Birch

20070078168 - Pyridine carboxylic acid derivatives as glucokinase modulators: A compound of Formula (I): wherein: A is phenyl or a 5- or 6-membered heteroaryl ring, optionally substituted; R1 and R2 are selected from hydrogen and methyl; with the proviso that at least one of R1 and R2 is methyl; or a salt, pro-drug or solvate thereof, are described. Their... Agent: Morgan Lewis & Bockius LLP

20070078169 - Substituted (4-aminocyclohexen-1-yl)phenyl and (4-aminocyclohexen-1-yl)pyridinyl compounds as 5-ht1f agonists: c

20070078170 - Process for the preparation of pioglitazone: The present invention relates to a new polymorphic form of 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl thiazolidine-2,4-dione of Formula I, commonly known as pioglitazone. It also relates to processes for the preparation of new polymorphic form of pioglitazone and pharmaceutical compositions that include the polymorphic form. It also relates to processes for the preparation of... Agent: Ranbaxy Inc.

20070078172 - Mao-b inhibitors useful for treating obesity: The invention provides a method of treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance) in a mammal by administering to the mammal a therapeutically effective amount of an irreversible MAO-B inhibitor.... Agent: Vance Intellectual Property, PC

20070078171 - Synergistic insecticide mixtures: The invention relates to insecticidal mixtures comprising, as active compounds, in each case two compounds from the series of the chloronicotinyl insecticides, and to the use of these mixtures for controlling animal pests.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070078173 - Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors: α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.... Agent: Banner & Witcoff

20070078174 - Tizanidine compositions and methods of treatment using the compositions: The invention is directed to methods of treating spasticity in patient having a neurological disease comprising administering to a patient in need of such treatment a tizanidine formulation providing a tizanidine blood concentration of at least about 900 pg/ml for about five hours, wherein the formulation is administered prior to... Agent: Kenyon & Kenyon LLP

20070078175 - Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof: e

20070078176 - Keratinocyte growth factor receptor-tyrosine specific inhibitors for the prevention of cancer metastatis: Compounds and methods for treating, inhibiting, or delaying the onset of cancer in a subject by administering a therapeutically effective amount of a keratinocyte growth factor receptor tyrosine kinase (KGFR TK) inhibitor to the subject in need of such treatment. Also provided are compounds and methods for the treating, inhibiting,... Agent: Calfee Halter & Griswold, LLP

20070078177 - Methods and compositions for treating non age related hearing impairment in a subject: The invention provides methods for treating non-age related hearing impairments, especially sensorineural and neural hearing loss, in a subject in need of such treatment.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20070078178 - Antidiabetic compounds comprising benzofuran and benzothiophene derivatives: e

20070078179 - Use of a fibrate and orlistat for the treatment of obesity: The present invention relates to the use of a fibrate and orlistat to treat patients suffering from obesity.... Agent: Merchant & Gould PC

20070078180 - Methods and compositions for stabilizing an antioxidant: The present invention is a method of stabilizing an antioxidant by adding a carotenoid. According to one embodiment, the method includes stabilizing the antioxidant by reducing oxidation. The method can also include enhancing the beneficial effects of the antioxidant. The antioxidant can be CoQ10. In one aspect of the invention,... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070078182 - Compounds and methods for delivery of prostacyclin analogs: This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and... Agent: Foley And Lardner LLP Suite 500

20070078183 - Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same: The present invention relates to a tetrafluorobenzyl derivative and a pharmaceutical composition for prevention and treatment of acute and chronic neurodegenerative disease in central nervous system and ophthalmic diseases containing the same. The tetrafluorobenzyl derivative of the present invention can effectively be used to prevent and treat chronic neurodegenerative diseases... Agent: Seed Intellectual Property Law Group PLLC

20070078181 - Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints: This invention relates to the use of beta-3-adrenoceptor agonists for the prevention and treatment of kidney damage and/or functional bladder complaints, particularly bladder complaints of neurogenic origin as the result of spinal cord injury.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070078184 - Amino alcohol derivatives, medicinal composition containing the same, and use of these: a prodrug thereof, or pharmaceutical acceptable salts thereof, wherein R1 is hydrogen or lower alkyl; each of R2 and R3 is independently hydrogen or lower alkyl; each of R4, R5 and R6 is independently hydrogen, halogen, lower alkyl or lower alkoxy; R7 is hydrogen or lower alkyl; R8 is hydrogen,... Agent: Sughrue Mion, PLLC

20070078185 - Methods and compositions for controlling invertebrate pests: The invention features methods for controlling invertebrate pests using compositions that disrupt tyrosine decarboxylase activity.... Agent: Clark & Elbing LLP

20070078186 - Methods for treating transthyretin amyloid diseases: Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed.... Agent: Jones Day

20070078187 - Methods for treating viral infections using polyamine analogs: Methods for treating viral infections using polyamine analogs, including mitoguazone (MGBG), are provided. In these methods, polyamine analogs destroy macrophages that act as viral reservoirs, facilitating the destruction of the viruses that dwell within the macrophages. Examples of viral infections that may be treated with the present methods include, but... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20070078188 - Compositions comprising and methods of using norfluoxetine: The invention encompasses methods of using racemic and enantiomerically pure norfluoxetine, as well as pharmaceutical compositions, pharmaceutical unit dosage forms, and kits comprising racemic and enantiomerically pure norfluoxetine. In particular, the invention encompasses a method of inhibiting or reducing the production of PGE2. The invention further encompasses a method of... Agent: Jones Day

20070078189 - Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders: wherein R1, R2, R3 and R4 are as defined herein. The invention also discloses methods of preparation, pharmaceutical compositions, and methods of disease treatment utilizing pharmaceutical compositions comprising these compounds. The compounds of this invention are novel therapeutic agents for the treatment of cancer, diabetes, metabolic diseases and skin disorders... Agent: Dla Piper US LLP